Last updated Septmber 2023 - School of Pharmacy
1.
Erenburg N, Hamed R, Shaul C, Perucca E, Bialer M. Comparative activity of the enantiomers of fenfluramine and norfenfluramine in rodent seizure models, and relationship with their concentrations in plasma and brain. Epilepsia [Internet]. 2023;64(6):1673–83. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85152780764&doi=10.1111%252fepi.17598&partnerID=40&md5=b350ba7da0a867fe8cc0e1b15963b4a4
2.
Perucca E, White HS, Bialer M. New GABA-Targeting Therapies for the Treatment of Seizures and Epilepsy: II. Treatments in Clinical Development. CNS Drugs [Internet]. 2023;37(9):781–95. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85168531667&doi=10.1007%252fs40263-023-01025-4&partnerID=40&md5=a421f57dbc07918950b2e4b860d4440f
3.
Perucca E, Bialer M, White HS. New GABA-Targeting Therapies for the Treatment of Seizures and Epilepsy: I. Role of GABA as a Modulator of Seizure Activity and Recently Approved Medications Acting on the GABA System. CNS Drugs [Internet]. 2023;37(9):755–79. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85168457944&doi=10.1007%252fs40263-023-01027-2&partnerID=40&md5=74dbb09e29d6106cb09672dabf739c12
4.
Goldstein R, Jacobs AR, Zighan L, Gronich N, Bialer M, Muszkat M. Interactions Between Direct Oral Anticoagulants (DOACs) and Antiseizure Medications: Potential Implications on DOAC Treatment. CNS Drugs [Internet]. 2023; Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85149245364&doi=10.1007%252fs40263-023-00990-0&partnerID=40&md5=a15e13faf6b0e8a8509722e73cc2d6f7
5.
Bialer M, Johannessen SI, Koepp MJ, Levy RH, Perucca E, Perucca P, et al. Progress report on new antiepileptic drugs: A summary of the Sixteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVI): I. Drugs in preclinical and early clinical development. Epilepsia [Internet]. 2022;63(11):2865–82. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85136924736&doi=10.1111%252fepi.17373&partnerID=40&md5=9ee09403e4524e04756d8b69a6db95ea
6.
Bialer M, Johannessen SI, Koepp MJ, Levy RH, Perucca E, Perucca P, et al. Progress report on new antiepileptic drugs: A summary of the Sixteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVI): II. Drugs in more advanced clinical development. Epilepsia [Internet]. 2022;63(11):2883–910. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85135844608&doi=10.1111%252fepi.17376&partnerID=40&md5=e5796818e0adb2282523bf2f5dbf08f9
7.
Wanounou M, Caraco Y, Levy RH, Bialer M, Perucca E. Clinically Relevant Interactions Between Ritonavir-Boosted Nirmatrelvir and Concomitant Antiseizure Medications: Implications for the Management of COVID-19 in Patients with Epilepsy. Clinical Pharmacokinetics [Internet]. 2022;61(9):1219–36. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85135275106&doi=10.1007%252fs40262-022-01152-z&partnerID=40&md5=6afca7d5ad7a60b0824cf8867bb609b8
8.
Shaul C, Blotnick S, Adar L, Muszkat M, Bialer M, Caraco Y. Phenytoin Metabolic Ratio, a Marker of CYP2C9 Activity, is Superior to the CYP2C9 Genotype as a Predictor of (S)-Warfarin Clearance. Clinical Pharmacokinetics [Internet]. 2022;61(8):1187–98. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85131786092&doi=10.1007%252fs40262-022-01141-2&partnerID=40&md5=e7dd1a495e65381f29cd7ed05e36f07a
9.
Bialer M, Perucca E. Lorcaserin for Dravet Syndrome: A Potential Advance Over Fenfluramine? CNS Drugs [Internet]. 2022;36(2):113–22. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85123883921&doi=10.1007%252fs40263-022-00896-3&partnerID=40&md5=6e776fd5209cdf0b767e2b5eb4d25e93
10.
Odi R, Bibi D, Shusterman B, Erenburg N, Shaul C, Supuran CT, et al. Synthesis and enantioselective pharmacokinetic/ pharmacodynamic analysis of new CNS-active sulfamoylphenyl carbamate derivatives. International Journal of Molecular Sciences [Internet]. 2021;22(7). Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85103017752&doi=10.3390%252fijms22073361&partnerID=40&md5=1393da95b972a518d628d2bb6b4a4577
11.
Franco V, Bialer M, Perucca E. Cannabidiol in the treatment of epilepsy: Current evidence and perspectives for further research. Neuropharmacology [Internet]. 2021;185. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85099194935&doi=10.1016%252fj.neuropharm.2020.108442&partnerID=40&md5=4d5ddb0478ae225d2eeb4d69407c12bb
12.
Odi R, Franco V, Perucca E, Bialer M. Bioequivalence and switchability of generic antiseizure medications (ASMs): A re-appraisal based on analysis of generic ASM products approved in Europe. Epilepsia [Internet]. 2021;62(2):285–302. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85099080555&doi=10.1111%252fepi.16802&partnerID=40&md5=7905de76d5ba50bfb9de47d363050233
13.
Franco V, Gershkovich P, Perucca E, Bialer M. The Interplay Between Liver First-Pass Effect and Lymphatic Absorption of Cannabidiol and Its Implications for Cannabidiol Oral Formulations. Clinical Pharmacokinetics [Internet]. 2020;59(12):1493–500. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85089370675&doi=10.1007%252fs40262-020-00931-w&partnerID=40&md5=dece6e9e3b28c418ba5e128eb707831e
14.
Bialer M, Johannessen SI, Koepp MJ, Levy RH, Perucca E, Perucca P, et al. Progress report on new antiepileptic drugs: A summary of the Fifteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XV). I. Drugs in preclinical and early clinical development. Epilepsia [Internet]. 2020;61(11):2340–64. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85096746689&doi=10.1111%252fepi.16725&partnerID=40&md5=bc2e2925371baf35d9834ef090415441
15.
Bialer M, Johannessen SI, Koepp MJ, Levy RH, Perucca E, Perucca P, et al. Progress report on new antiepileptic drugs: A summary of the Fifteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XV). II. Drugs in more advanced clinical development. Epilepsia [Internet]. 2020;61(11):2365–85. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85096669586&doi=10.1111%252fepi.16726&partnerID=40&md5=9b3cba544a250798870cd5ccffff9195
16.
Bialer M, Perucca E. Response: Cannabidiol antiseizure activity and its interactions with clobazam: “It’s déjà vu all over again” Yogi Berra. Epilepsia [Internet]. 2020;61(8):1793–4. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85087448250&doi=10.1111%252fepi.16601&partnerID=40&md5=e59147b3fb26e5838cd77cd093f22147
17.
Odi R, Bibi D, Wager T, Bialer M. A perspective on the physicochemical and biopharmaceutic properties of marketed antiseizure drugs—From phenobarbital to cenobamate and beyond. Epilepsia [Internet]. 2020;61(8):1543–52. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85087314910&doi=10.1111%252fepi.16597&partnerID=40&md5=68dd8d94933328de31c4ccb115cacd46
18.
Perucca E, Bialer M. Critical Aspects Affecting Cannabidiol Oral Bioavailability and Metabolic Elimination, and Related Clinical Implications. CNS Drugs [Internet]. 2020;34(8):795–800. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85086094883&doi=10.1007%252fs40263-020-00741-5&partnerID=40&md5=7c28fe3ac837b125e5440b04c308c3c9
19.
Bialer M, Perucca E. Does cannabidiol have antiseizure activity independent of its interactions with clobazam? An appraisal of the evidence from randomized controlled trials. Epilepsia [Internet]. 2020;61(6):1082–9. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85085622726&doi=10.1111%252fepi.16542&partnerID=40&md5=bdfc0190b9166526cf2e33c83fab0d1b
20.
Bibi D, Bialer M. Pharmacokinetic and pharmacodynamic analysis of (2S,3S)-sec-butylpropylacetamide (SPD) in rats and pigs—A CNS-active stereoisomer of SPD. Epilepsia [Internet]. 2020;61(1):149–56. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85077988031&doi=10.1111%252fepi.16411&partnerID=40&md5=995e6c1c68b8c5951e040c0c1aa84681
21.
Bialer M, Cross H, Hedrich UBS, Lagae L, Lerche H, Loddenkemper T. Novel treatment approaches and pediatric research networks in status epilepticus. Epilepsy and Behavior [Internet]. 2019;101. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85075498024&doi=10.1016%252fj.yebeh.2019.106564&partnerID=40&md5=4eb519092a4bbfd8336f70e7b10e9294
22.
Lin YL, Bialer M, Cabrera RM, Finnell RH, Wlodarczyk BJ. Teratogenicity of valproic acid and its constitutional isomer, amide derivative valnoctamide in mice. Birth Defects Research [Internet]. 2019;111(14):1013–23. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85055047544&doi=10.1002%252fbdr2.1406&partnerID=40&md5=5bb27a022cb18a362a08d430410cdcab
23.
Bialer M, Johannessen SI, Koepp MJ, Levy RH, Perucca E, Tomson T, et al. A summary of data presented at the XIV conference on new antiepileptic drug and devices (EILAT XIV). Epilepsy Research [Internet]. 2019;153:66–7. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85063113192&doi=10.1016%252fj.eplepsyres.2019.03.002&partnerID=40&md5=b2aaf3fe53b4bf7478560a4358aa1d45
24.
Haines KM, Matson LM, Dunn EN, Ardinger CE, Lee-Stubbs R, Bibi D, et al. Comparative efficacy of valnoctamide and sec-butylpropylacetamide (SPD) in terminating nerve agent–induced seizures in pediatric rats. Epilepsia [Internet]. 2019;60(2):315–21. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85059621321&doi=10.1111%252fepi.14630&partnerID=40&md5=9272d4d83beafb4bb8bf4ddce6bf6b04
25.
Bibi D, Shusterman B, Nocentini A, Supuran CT, Bialer M. Stereoselective pharmacokinetic and pharmacodynamic analysis of a CNS-active sulphamoylphenyl carbamate derivative. Journal of Enzyme Inhibition and Medicinal Chemistry [Internet]. 2019;34(1):1078–82. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85066850110&doi=10.1080%252f14756366.2019.1612887&partnerID=40&md5=b37847875cb5e152439c01a8f6eea878
26.
Bialer M, Johannessen SI, Koepp MJ, Levy RH, Perucca E, Tomson T, et al. Progress report on new antiepileptic drugs: A summary of the Fourteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV). I. Drugs in preclinical and early clinical development. Epilepsia [Internet]. 2018;59(10):1811–41. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85055442949&doi=10.1111%252fepi.14557&partnerID=40&md5=d5c059f3bc91d9dae1537b8d8c7618b2
27.
Bialer M, Johannessen SI, Koepp MJ, Levy RH, Perucca E, Tomson T, et al. Progress report on new antiepileptic drugs: A summary of the Fourteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV). II. Drugs in more advanced clinical development. Epilepsia [Internet]. 2018;59(10):1842–66. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85055430738&doi=10.1111%252fepi.14555&partnerID=40&md5=6476a9312bebac4cf9be776dc44d7fe1
28.
Kudin AP, Mawasi H, Eisenkraft A, Elger CE, Bialer M, Kunz WS. Mitochondrial liver toxicity of valproic acid and its acid derivatives is related to inhibition of α-lipoamide dehydrogenase. International Journal of Molecular Sciences [Internet]. 2017;18(9). Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85029164200&doi=10.3390%252fijms18091912&partnerID=40&md5=15bf3109dfa7603a254a2a761e82cd9e
29.
Bibi D, Mawasi H, Nocentini A, Supuran CT, Wlodarczyk B, Finnell RH, et al. Design and Comparative Evaluation of the Anticonvulsant Profile, Carbonic-Anhydrate Inhibition and Teratogenicity of Novel Carbamate Derivatives of Branched Aliphatic Carboxylic Acids with 4-Aminobenzensulfonamide. Neurochemical Research [Internet]. 2017;42(7):1972–82. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85014635226&doi=10.1007%252fs11064-017-2216-x&partnerID=40&md5=ff76957b908435f481558465a25ea5ae
30.
Weiser M, Levi L, Levine SZ, Bialer M, Shekh-Ahmad T, Matei V, et al. A randomized, double-blind, placebo- and risperidone-controlled study on valnoctamide for acute mania. Bipolar Disorders [Internet]. 2017;19(4):285–94. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85020431508&doi=10.1111%252fbdi.12506&partnerID=40&md5=8c9a872520852bf316a5b1eaba760b4b
31.
Kaufmann D, West PJ, Smith MD, Yagen B, Bialer M, Devor M, et al. sec-Butylpropylacetamide (SPD), a new amide derivative of valproic acid for the treatment of neuropathic and inflammatory pain. Pharmacological Research [Internet]. 2017;117:129–39. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85007001226&doi=10.1016%252fj.phrs.2016.11.030&partnerID=40&md5=6ec1b8997d491432ce5d7271f787c569
32.
Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: A summary of the Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII). Epilepsia [Internet]. 2017;58(2):181–221. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85010549236&doi=10.1111%252fepi.13634&partnerID=40&md5=ae3d18ce278f9a507c9c75fc887b5582
33.
Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS, et al. Seizure detection and neuromodulation: A summary of data presented at the XIII conference on new antiepileptic drug and devices (EILAT XIII). Epilepsy Research [Internet]. 2017;130:27–36. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85009990165&doi=10.1016%252fj.eplepsyres.2017.01.004&partnerID=40&md5=80e6872250a241046a0ab6b368ab449c
34.
Shaul C, Blotnick S, Muszkat M, Bialer M, Caraco Y. Quantitative Assessment of CYP2C9 Genetic Polymorphisms Effect on the Oral Clearance of S-Warfarin in Healthy Subjects. Molecular Diagnosis and Therapy [Internet]. 2017;21(1):75–83. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84996538160&doi=10.1007%252fs40291-016-0247-7&partnerID=40&md5=5ec697209261d6ba4040a1674a1a01a9
35.
Kaufmann D, Bates EA, Yagen B, Bialer M, Saunders GH, Wilcox K, et al. Sec -Butylpropylacetamide (SPD) has antimigraine properties. Cephalalgia [Internet]. 2016;36(10):924–35. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84983027625&doi=10.1177%252f0333102415612773&partnerID=40&md5=cd3254573509369b06adc03cfd5d4a6e
36.
Mawasi H, Bibi D, Shekh-Ahmad T, Shaul C, Blotnik S, Bialer M. Pharmacokinetic-pharmacodynamic correlation and brain penetration of sec-butylpropylacetamide, a new CNS drug possessing unique activity against status epilepticus. Molecular Pharmaceutics [Internet]. 2016;13(7):2492–6. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84979022657&doi=10.1021%252facs.molpharmaceut.6b00221&partnerID=40&md5=d5d22de0aa8f2a5bfceebfcefdba74a3
37.
Mawasi H, Bibi D, Bialer M. Design and comparative anticonvulsant activity assessment of CNS-active alkyl-carbamoyl imidazole derivatives. Bioorganic and Medicinal Chemistry [Internet]. 2016;24(18):4246–53. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84979695958&doi=10.1016%252fj.bmc.2016.07.018&partnerID=40&md5=a19cd7ad1821145ce9bbc798818f73b1
38.
Korczyn AD, Schachter SC, Amlerova J, Bialer M, van Emde Boas W, Brázdil M, et al. Third International Congress on Epilepsy, Brain and Mind: Part 1. Epilepsy and Behavior [Internet]. 2015;50:116–37. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84941166168&doi=10.1016%252fj.yebeh.2015.06.044&partnerID=40&md5=4a041e8c3a06510b1f01d09e074c0cc1
39.
Wlodarczyk BJ, Ogle K, Lin LY, Bialer M, Finnell RH. Comparative teratogenicity analysis of valnoctamide, risperidone, and olanzapine in mice. Bipolar Disorders [Internet]. 2015;17(6):615–25. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84941022498&doi=10.1111%252fbdi.12325&partnerID=40&md5=ca743622ad94e214c6c61772159e2f51
40.
Shekh-Ahmad T, Mawasi H, McDonough JH, Yagen B, Bialer M. The potential of sec-butylpropylacetamide (SPD) and valnoctamide and their individual stereoisomers in status epilepticus. Epilepsy and Behavior [Internet]. 2015;49:298–302. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84938953746&doi=10.1016%252fj.yebeh.2015.04.012&partnerID=40&md5=c7ae3346de394232608ddaf7a929d028
41.
Mawasi H, Shekh-Ahmad T, Finnell RH, Wlodarczyk BJ, Bialer M. Pharmacodynamic and pharmacokinetic analysis of CNS-active constitutional isomers of valnoctamide and sec-butylpropylacetamide - Amide derivatives of valproic acid. Epilepsy and Behavior [Internet]. 2015;46:72–8. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84937978253&doi=10.1016%252fj.yebeh.2015.02.040&partnerID=40&md5=e396af5203105a3136be9038d8791c68
42.
Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: A summary of the Twelfth Eilat Conference (EILAT XII). Epilepsy Research [Internet]. 2015;111:85–141. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84924308270&doi=10.1016%252fj.eplepsyres.2015.01.001&partnerID=40&md5=6e825285cedfbd2e62408e57fafa82f0
43.
Shekh-Ahmad T, Mawasi H, McDonough JH, Finnell RH, Wlodarczyk BJ, Yavin E, et al. Enantioselective pharmacodynamic and pharmacokinetic analysis of two chiral CNS-active carbamate derivatives of valproic acid. Epilepsia [Internet]. 2014;55(12):1944–52. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84920020568&doi=10.1111%252fepi.12857&partnerID=40&md5=ebce87a610bf021d1d020fd7bd33320e
44.
Bar-Klein G, Swissa E, Kamintsky L, Shekh-Ahmad T, Saar-Ashkenazy R, Hubary Y, et al. Sec-Butyl-propylacetamide (SPD) and two of its stereoisomers rapidly terminate paraoxon-induced status epilepticus in rats. Epilepsia [Internet]. 2014;55(12):1953–8. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84919958050&doi=10.1111%252fepi.12838&partnerID=40&md5=a71976d570e2cc7056545fba34b65b27
45.
Shekh-Ahmad T, Hen N, Yagen B, McDonough JH, Finnell RH, Wlodarczyk BJ, et al. Stereoselective anticonvulsant and pharmacokinetic analysis of valnoctamide, a CNS-active derivative of valproic acid with low teratogenic potential. Epilepsia [Internet]. 2014;55(2):353–61. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84894082208&doi=10.1111%252fepi.12480&partnerID=40&md5=9e8bf500413ff7009bf1ebceafdbcc84
46.
Karalis V, MacHeras P, Bialer M. Generic products of antiepileptic drugs: A perspective on bioequivalence, bioavailability, and formulation switches using monte carlo simulations. CNS Drugs [Internet]. 2014;28(1):69–77. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84893449689&doi=10.1007%252fs40263-013-0112-8&partnerID=40&md5=52ac10bd52fcf78f6fda312b1c388329
47.
Shekh-Ahmad T, Hen N, McDonough JH, Yagen B, Bialer M. Valnoctamide and sec-butyl-propylacetamide (SPD) for acute seizures and status epilepticus. Epilepsia [Internet]. 2013;54(SUPPL. 6):99–102. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84891543694&doi=10.1111%252fepi.12290&partnerID=40&md5=cc30baec8941ef92d1678aaab5642df0
48.
Neuman MG, Nanau RM, Shekh-Ahmad T, Yagen B, Bialer M. Valproic acid derivatives signal for apoptosis and repair in vitro. Clinical Biochemistry [Internet]. 2013;46(15):1532–7. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84884350937&doi=10.1016%252fj.clinbiochem.2013.07.003&partnerID=40&md5=60c0b57326ea2a1559d0ecb67e6fe728
49.
Karalis V, Bialer M, Macheras P. Quantitative assessment of the switchability of generic products. European Journal of Pharmaceutical Sciences [Internet]. 2013;50(3–4):476–83. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84883674084&doi=10.1016%252fj.ejps.2013.08.023&partnerID=40&md5=868a714ded3a60bc00a0e5a3ee885938
50.
Mareš P, Kubová H, Hen N, Yagen B, Bialer M. Derivatives of valproic acid are active against pentetrazol-induced seizures in immature rats. Epilepsy Research [Internet]. 2013;106(1–2):64–73. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84883284143&doi=10.1016%252fj.eplepsyres.2013.06.001&partnerID=40&md5=322e9d84867bf26e9aa36251aa411cc5
51.
Hen N, Shekh-Ahmad T, Yagen B, McDonough JH, Finnell RH, Wlodarczyk B, et al. Stereoselective pharmacodynamic and pharmacokinetic analysis of sec -butylpropylacetamide (SPD), a new CNS-Active derivative of valproic acid with unique activity against status epilepticus. Journal of Medicinal Chemistry [Internet]. 2013;56(16):6467–77. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84883200078&doi=10.1021%252fjm4007565&partnerID=40&md5=3916737bf8c729130db423374484140d
52.
Onishi Y, Okada A, Noyori H, Okamura A, Hen N, Yagen B, et al. Teratology study of amide derivatives of branched aliphatic carboxylic acids with 4-aminobenzensulfonamide in NMRI mice. Birth Defects Research Part B - Developmental and Reproductive Toxicology [Internet]. 2013;98(4):318–27. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84885872381&doi=10.1002%252fbdrb.21068&partnerID=40&md5=5226a891491154c57eb643b353277e5a
53.
Elger C, Bialer M, Falcão A, Vaz-Da-Silva M, Nunes T, Almeida L, et al. Pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine at steady state in healthy volunteers. Epilepsia [Internet]. 2013;54(8):1453–61. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84881177072&doi=10.1111%252fepi.12242&partnerID=40&md5=58cf95b357a3ab447d6e4a21eba19638
54.
Bialer M, Shekh-Ahmad T, Braun TL, Halvorsen MB. Comparative steady-state pharmacokinetic evaluation of immediate-release topiramate and USL255, a once-daily extended-release topiramate formulation. Epilepsia [Internet]. 2013;54(8):1444–52. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84881163836&doi=10.1111%252fepi.12225&partnerID=40&md5=cede6ca3eac8217508446ce770da6d8e
55.
Modi HR, Basselin M, Taha AY, Li LO, Coleman RA, Bialer M, et al. Propylisopropylacetic acid (PIA), a constitutional isomer of valproic acid, uncompetitively inhibits arachidonic acid acylation by rat acyl-CoA synthetase 4: A potential drug for bipolar disorder. Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids [Internet]. 2013;1831(4):880–6. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84873701434&doi=10.1016%252fj.bbalip.2013.01.008&partnerID=40&md5=4e8df2bfb6263ee3efedd06a1da53b03
56.
Pouliot W, Bialer M, Hen N, Shekh-Ahmad T, Kaufmann D, Yagen B, et al. A comparative electrographic analysis of the effect of sec-butyl-propylacetamide on pharmacoresistant status epilepticus. Neuroscience [Internet]. 2013;231:145–56. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84871999498&doi=10.1016%252fj.neuroscience.2012.11.005&partnerID=40&md5=eb5a72e03269eabbf116361353c37e18
57.
Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: A summary of the Eleventh Eilat Conference (EILAT XI). Epilepsy Research [Internet]. 2013;103(1):2–30. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84872163082&doi=10.1016%252fj.eplepsyres.2012.10.001&partnerID=40&md5=676d10cdd05c0582161c490232b5e5fa
58.
Smith P, Bialer M. The borderland of epilepsy: Chairs’ Symposium, 10th European Congress on Epileptology, London–October 1, 2012. Introduction. Epilepsia [Internet]. 2012;53 Suppl 7:1–2. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84872186098&partnerID=40&md5=5f303b29c7ad7b0b0aa7677479b525aa
59.
Bialer M. Comments on the working group’s 2012 review of the Program. Epilepsia [Internet]. 2012;53(10):1844–6. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84867167277&doi=10.1111%252fj.1528-1167.2012.03682.x&partnerID=40&md5=d7f36928b2600f1f87e76afebc91c868
60.
Bialer M. Chemical properties of antiepileptic drugs (AEDs). Advanced Drug Delivery Reviews [Internet]. 2012;64(10):887–95. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84862858037&doi=10.1016%252fj.addr.2011.11.006&partnerID=40&md5=47664bbb57f29d2269fad3a6b52317a8
61.
Bialer M, Soares-Da-Silva P. Pharmacokinetics and drug interactions of eslicarbazepine acetate. Epilepsia [Internet]. 2012;53(6):935–46. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84861792459&doi=10.1111%252fj.1528-1167.2012.03519.x&partnerID=40&md5=d9d8bc7dfbe744731cfa1ca47f2eb51b
62.
Bejarano-Achache I, Levy L, Mlynarsky L, Bialer M, Muszkat M, Caraco Y. Effects of CYP4F2 Polymorphism on Response to Warfarin During Induction Phase: A Prospective, Open-Label, Observational Cohort Study. Clinical Therapeutics [Internet]. 2012;34(4):811–23. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84859565615&doi=10.1016%252fj.clinthera.2012.02.009&partnerID=40&md5=1826e322ddc1b55b717f2e7fe089fbcb
63.
Hen N, Bialer M, Yagen B. Syntheses and evaluation of anticonvulsant activity of novel branched alkyl carbamates. Journal of Medicinal Chemistry [Internet]. 2012;55(6):2835–45. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84858713945&doi=10.1021%252fjm201751x&partnerID=40&md5=c1018fb2362e5a4f7ea7a6567076c924
64.
Shekh-Ahmad T, Bialer M, Yavin E. Synthesis and anticonvulsant evaluation of dimethylethanolamine analogues of valproic acid and its tetramethylcyclopropyl analogue. Epilepsy Research [Internet]. 2012;98(2–3):238–46. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84856504238&doi=10.1016%252fj.eplepsyres.2011.10.005&partnerID=40&md5=7c7de773065065457543829fcf1cd24a
65.
Bialer M. How did phenobarbital’s chemical structure affect the development of subsequent antiepileptic drugs (AEDs)? Epilepsia [Internet]. 2012;53 Suppl 8:3–11. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84873166641&doi=10.1111%252fepi.12024&partnerID=40&md5=681ca6bb158d7da7180b0081bf921fa2
66.
Bialer M, Smith PE. Special issue: Phenobarbital: the Centenary - 10th European Congress on Epileptology, London - October 1, 2012. Introduction. Epilepsia [Internet]. 2012;53 Suppl 8:1–2. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84873164144&partnerID=40&md5=fe8d363266900a5ee6903c804efc7784
67.
Bialer M. Why are antiepileptic drugs used for nonepileptic conditions? Epilepsia [Internet]. 2012;53 Suppl 7:26–33. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84872188829&doi=10.1111%252fj.1528-1167.2012.03712.x&partnerID=40&md5=54dcedb3529507f0899d248ea89405aa
68.
Chang P, Orabi B, Deranieh RM, Dham M, Hoeller O, Shimshoni JA, et al. The antiepileptic drug valproic acid and other medium-chain fatty acids acutely reduce phosphoinositide levels independently of inositol in Dictyostelium. DMM Disease Models and Mechanisms [Internet]. 2012;5(1):115–24. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84862907498&doi=10.1242%252fdmm.008029&partnerID=40&md5=cf2b9e4007b627c656e6ff07eaed2e1b
69.
White HS, Alex AB, Pollock A, Hen N, Shekh-Ahmad T, Wilcox KS, et al. A new derivative of valproic acid amide possesses a broad-spectrum antiseizure profile and unique activity against status epilepticus and organophosphate neuronal damage. Epilepsia [Internet]. 2012;53(1):134–46. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84855441268&doi=10.1111%252fj.1528-1167.2011.03338.x&partnerID=40&md5=284ed61f96444d575391868d38009869
70.
Pessah N, Yagen B, Hen N, Shimshoni JA, Wlodarczyk B, Finnell RH, et al. Design and pharmacological activity of glycinamide and N-methoxy amide derivatives of analogs and constitutional isomers of valproic acid. Epilepsy and Behavior [Internet]. 2011;22(3):461–8. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-80055000175&doi=10.1016%252fj.yebeh.2011.08.026&partnerID=40&md5=31af73f6c75236c5da917124215e61ce
71.
Lambrecht LJ, Shekh-Ahmad T, Todd WM, Halvorsen MB, Bialer M. Comparative pharmacokinetic analysis of USL255, a new once-daily extended-release formulation of topiramate. Epilepsia [Internet]. 2011;52(10):1877–83. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-80053574023&doi=10.1111%252fj.1528-1167.2011.03183.x&partnerID=40&md5=43318263d8729d1cfcadfe341c420ec3
72.
Hen N, Bialer M, Yagen B, Maresca A, Aggarwal M, Robbins AH, et al. Anticonvulsant 4-aminobenzenesulfonamide derivatives with branched-alkylamide moieties: X-ray crystallography and inhibition studies of human carbonic anhydrase isoforms I, II, VII, and XIV. Journal of Medicinal Chemistry [Internet]. 2011;54(11):3977–81. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-79958174646&doi=10.1021%252fjm200209n&partnerID=40&md5=c1288da8267653e2f6768cb225123b8c
73.
Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: A summary of the Tenth Eilat Conference (EILAT X). Epilepsy Research [Internet]. 2010;92(2–3):89–124. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-78650178478&doi=10.1016%252fj.eplepsyres.2010.09.001&partnerID=40&md5=cba99b79ddef603f107386377d63dbc9
74.
Pessah N, Kaufmann D, Yagen B, Hen N, Wlodarczyk B, Finnell RH, et al. Comparative pharmacodynamic and pharmacokinetic analysis of two anticonvulsant halo derivatives of 2,2,3,3-tetramethylcyclopropanecarboxamide, an amide of a cyclic analog of valproic acid. Epilepsia [Internet]. 2010;51(10):1944–53. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-78649267959&doi=10.1111%252fj.1528-1167.2010.02684.x&partnerID=40&md5=4ec62f8dc40d585cd4461f831c33a378
75.
Bialer M, Midha KK. Generic products of antiepileptic drugs: A perspective on bioequivalence and interchangeability. Epilepsia [Internet]. 2010;51(6):941–50. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-77954627471&doi=10.1111%252fj.1528-1167.2010.02573.x&partnerID=40&md5=23a3a7ac628d74b5649861ce036b0e93
76.
Kaufmann D, Yagen B, Minert A, Wlodarczyk B, Finnell RH, Schurig V, et al. Evaluation of the antiallodynic, teratogenic and pharmacokinetic profile of stereoisomers of valnoctamide, an amide derivative of a chiral isomer of valproic acid. Neuropharmacology [Internet]. 2010;58(8):1228–36. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-77952884895&doi=10.1016%252fj.neuropharm.2010.03.004&partnerID=40&md5=17a2b518ed5404fa6685d9acbd051926
77.
Hen N, Bialer M, Wlodarczyk B, Finnell RH, Yagen B. Syntheses and evaluation of anticonvulsant profile and teratogenicity of novel amide derivatives of branched aliphatic carboxylic acids with 4-aminobenzensulfonamide. Journal of Medicinal Chemistry [Internet]. 2010;53(10):4177–86. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-77952708293&doi=10.1021%252fjm100170w&partnerID=40&md5=62f2c6d698ac1bbbc1fd80ffadeec74b
78.
Shimshoni JA, Yagen B, Wlodarczyk B, Finnell RH, Schurig V, Bialer M. Evaluation of stereoselective anticonvulsant, teratogenic, and pharmacokinetic profile of valnoctylurea (capuride): A chiral stereoisomer of valproic acid urea derivative. Epilepsia [Internet]. 2010;51(3):323–32. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-77749270564&doi=10.1111%252fj.1528-1167.2009.02241.x&partnerID=40&md5=5f07b568b0b91328c82f8102c72530a3
79.
Bialer M, White HS. Key factors in the discovery and development of new antiepileptic drugs. Nature Reviews Drug Discovery [Internet]. 2010;9(1):68–82. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-74049163222&doi=10.1038%252fnrd2997&partnerID=40&md5=9356a547a4b4c9cc6597b43dfeeb939b
80.
Bialer M. Pharmacodynamic and pharmacokinetic characteristics of intravenous drugs in status epilepticus. Epilepsia [Internet]. 2009;50:44–8. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-80053580843&doi=10.1111%252fj.1528-1167.2009.02348.x&partnerID=40&md5=8a2cd4cf9062b396fe4d3ea7916d33d7
81.
Kaufmann D, Bialer M, Shimshoni JA, Devor M, Yagen B. Synthesis and evaluation of antiallodynic and anticonvulsant activity of novel amide and urea derivatives of valproic acid analogues. Journal of Medicinal Chemistry [Internet]. 2009;52(22):7236–48. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-70949087351&doi=10.1021%252fjm901229s&partnerID=40&md5=7c7f208f5b97fcd1f3cd0aa4c2147d43
82.
Okada A, Noyori H, Yagen B, Shimshoni JA, Bialer M, Fujiwara M. Anticonvulsant profile and teratogenic evaluation of potent new analogues of a valproic acid urea derivative in NMRI mice. Birth Defects Research Part B - Developmental and Reproductive Toxicology [Internet]. 2009;86(5):394–401. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-70350704692&doi=10.1002%252fbdrb.20209&partnerID=40&md5=afc876f81fdb77cf39555f2a3b3577a8
83.
Zannikos P, Novak G, Yao C, Verhaeghe T, Franc MA, Solanki B, et al. Pharmacokinetics of carisbamate (RWJ-333369) in healthy Japanese and Western subjects. Epilepsia [Internet]. 2009;50(8):1850–9. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-68149145489&doi=10.1111%252fj.1528-1167.2009.02081.x&partnerID=40&md5=17fd8d6f215087c2659d97481536fc46
84.
Almeida L, Bialer M, Soares-da Silva P. Eslicarbazepine Acetate [Internet]. The Treatment of Epilepsy: Third Edition. 2009. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-70349969112&doi=10.1002%252f9781444316667.ch38&partnerID=40&md5=86822cfa2b9f078168cc0a530a7863e8
85.
Pessah N, Bialer M, Wlodarczyk B, Finnell RH, Yagen B. α-fluoro-2,2,3,3-tetramethylcyclopropanecarboxamide, a novel potent anticonvulsant derivative of a cyclic analogue of valproic acid. Journal of Medicinal Chemistry [Internet]. 2009;52(8):2233–42. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-65249114616&doi=10.1021%252fjm900017f&partnerID=40&md5=783b6697340411d178510833e6b94a46
86.
Elger C, Bialer M. Epilepsia: Foreword. Epilepsia [Internet]. 2009;50(SUPPL. 4):1. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-64149098482&doi=10.1111%252fj.1528-1167.2009.02062.x&partnerID=40&md5=254730e32c3c8e8d43b2246e2bac7120
87.
Shimshoni JA, Dalton EC, Watson P, Yagen B, Bialer M, Harwood AJ. Evaluation of the effects of propylisopropylacetic acid (PIA) on neuronal growth cone morphology. Neuropharmacology [Internet]. 2009;56(4):831–7. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-60149085100&doi=10.1016%252fj.neuropharm.2009.01.014&partnerID=40&md5=a3d09ab1a4d7f22841f027b39d7fa018
88.
Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: A summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Research [Internet]. 2009;83(1):1–43. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-57849141134&doi=10.1016%252fj.eplepsyres.2008.09.005&partnerID=40&md5=cd9345e27ad670e09491f6ab68dd0d1a
89.
Okada A, Onishi Y, Yagen B, Shimshoni JA, Kaufmann D, Bialer M, et al. Tetramethylcyclopropyl analogue of the leading antiepileptic drug, valproic acid: Evaluation of the teratogenic effects of its amide derivatives in NMRI mice. Birth Defects Research Part A - Clinical and Molecular Teratology [Internet]. 2008;82(9):610–21. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-52249089980&doi=10.1002%252fbdra.20490&partnerID=40&md5=83750ec4749c286651e66ea7418a641d
90.
Shimshoni JA, Yagen B, Pessah N, Wlodarczyk B, Finnell RH, Bialer M. Anticonvulsant profile and teratogenicity of 3,3-dimethylbutanoylurea: A potential for a second generation drug to valproic acid. Epilepsia [Internet]. 2008;49(7):1202–12. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-47249142849&doi=10.1111%252fj.1528-1167.2008.01624.x&partnerID=40&md5=d892b2b32f372940d3d55945e57b4d05
91.
Shimshoni JA, Bialer M, Yagen B. Synthesis and anticonvulsant activity of aromatic tetramethylcyclopropanecarboxamide derivatives. Bioorganic and Medicinal Chemistry [Internet]. 2008;16(11):6297–305. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-44449083297&doi=10.1016%252fj.bmc.2008.03.051&partnerID=40&md5=147002e0082d9f52e6508e543b0dc401
92.
Kaufmann D, Yagen B, Minert A, Tal M, Devor M, Bialer M. Evaluation of the enantioselective antiallodynic and pharmacokinetic profile of propylisopropylacetamide, a chiral isomer of valproic acid amide. Neuropharmacology [Internet]. 2008;54(4):699–707. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-39049159090&doi=10.1016%252fj.neuropharm.2007.11.020&partnerID=40&md5=6fc67121b39df6d08ca376cb495c11f6
93.
Shimshoni JA, Bialer M, Wlodarczyk B, Finnell RH, Yagen B. Potent anticonvulsant urea derivatives of constitutional isomers of valproic acid. Journal of Medicinal Chemistry [Internet]. 2007;50(25):6419–27. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-37049031057&doi=10.1021%252fjm7009233&partnerID=40&md5=e24d6b1d4f2669ea7a5240fee20428d1
94.
Bialer M. Clinical pharmacology of parenteral use of antiepileptic drugs. Epilepsia [Internet]. 2007;48(SUPPL. 8):46–8. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-35748966403&doi=10.1111%252fj.1528-1167.2007.01348.x&partnerID=40&md5=0e39bb3b65fc6fc04727e7ca8fe2c289
95.
Bialer M. Generic products of antiepileptic drugs (AEDs): Is it an issue? Epilepsia [Internet]. 2007;48(10):1825–32. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-35148836175&doi=10.1111%252fj.1528-1167.2007.01272.x&partnerID=40&md5=55339caad1de7bf3964a1ba32a6f9b7d
96.
Perucca E, French J, Bialer M. Development of new antiepileptic drugs: challenges, incentives, and recent advances. Lancet Neurology [Internet]. 2007;6(9):793–804. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-34547828792&doi=10.1016%2fS1474-4422%2807%2970215-6&partnerID=40&md5=f78c63b949246166264fcb422de683bd
97.
Bialer M. Extended-release formulations for the treatment of epilepsy. CNS Drugs [Internet]. 2007;21(9):765–74. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-34548080314&doi=10.2165%252f00023210-200721090-00005&partnerID=40&md5=ec8210dc94c16fa369b11b58f46d24de
98.
Chien S, Yao C, Mertens A, Verhaeghe T, Solanki B, Doose DR, et al. An interaction study between the new antiepileptic and CNS drug carisbamate (RWJ-333369) and lamotrigine and valproic acid. Epilepsia [Internet]. 2007;48(7):1328–38. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-34447308489&doi=10.1111%252fj.1528-1167.2007.01037.x&partnerID=40&md5=505256c5dcde0076d783d69e143bda21
99.
Mannens GSJ, Hendrickx J, Janssen CGM, Chien S, Van Hoof B, Verhaeghe T, et al. The absorption, metabolism, and excretion of the novel neuromodulator RWJ-333369 (1,2-ethanediol, [1-2-chlorophenyl]-, 2-carbamate, [S]-) in humans. Drug Metabolism and Disposition [Internet]. 2007;35(4):554–65. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-34047122100&doi=10.1124%252fdmd.106.011940&partnerID=40&md5=6a38625fa79c04323b0b8992c0e62876
100.
Elger C, Bialer M, Cramer JA, Maia J, Almeida L, Soares-Da-Silva P. Eslicarbazepine acetate: A double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures. Epilepsia [Internet]. 2007;48(3):497–504. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-33847611166&doi=10.1111%252fj.1528-1167.2007.00984.x&partnerID=40&md5=841d68fac1d94f0b6d366bee40f4bcd0
101.
Shimshoni JA, Dalton EC, Jenkins A, Eyal S, Ewan K, Williams RSB, et al. The effects of central nervous system-active valproic acid constitutional isomers, cyclopropyl analogs, and amide derivatives on neuronal growth cone behavior. Molecular Pharmacology [Internet]. 2007;71(3):884–92. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-33847131550&doi=10.1124%252fmol.106.030601&partnerID=40&md5=f86a4fbb1ff3e16bf5b7729f6b78679c
102.
Bialer M, Yagen B. Valproic Acid: Second Generation. Neurotherapeutics [Internet]. 2007;4(1):130–7. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-33846228427&doi=10.1016%252fj.nurt.2006.11.007&partnerID=40&md5=ac9de712c0240f337242a5e6564fee1e
103.
Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T. Progress report on new antiepileptic drugs: A summary of the Eigth Eilat Conference (EILAT VIII). Epilepsy Research [Internet]. 2007;73(1):1–52. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-33846194013&doi=10.1016%252fj.eplepsyres.2006.10.008&partnerID=40&md5=fd07831293d2528c031fed510e09124a
104.
Sobol E, Yagen B, Lamb JG, White HS, Wlodarczyk BJ, Finnell RH, et al. Anticonvulsant activity, neural tube defect induction, mutagenicity and pharmacokinetics of a new potent antiepileptic drug, N-methoxy-2,2,3,3-tetramethylcyclopropane carboxamide. Epilepsy Research [Internet]. 2007;73(1):75–84. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-33846044344&doi=10.1016%252fj.eplepsyres.2006.08.004&partnerID=40&md5=344c42f7c62ec99ca88a42b666bb16ff
105.
Chien S, Bialer M, Solanki B, Verhaeghe T, Doose DR, Novak G, et al. Pharmacokinetic interaction study between the new antiepileptic and CNS drug RWJ-333369 and carbamazepine in healthy adults. Epilepsia [Internet]. 2006;47(11):1830–40. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-33750960656&doi=10.1111%252fj.1528-1167.2006.00815.x&partnerID=40&md5=9bc265cf7aee3cb664c553504125044f
106.
Yao C, Doose DR, Novak G, Bialer M. Pharmacokinetics of the new antiepileptic and CNS drug RWJ-333369 following single and multiple dosing to humans. Epilepsia [Internet]. 2006;47(11):1822–9. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-33750900787&doi=10.1111%252fj.1528-1167.2006.00814.x&partnerID=40&md5=eea464f414024bf7f5cb586897b0716c
107.
Eyal S, Lamb JG, Smith-Yockman M, Yagen B, Fibach E, Altschuler Y, et al. The antiepileptic and anticancer agent, valproic acid, induces P-glycoprotein in human tumour cell lines and in rat liver. British Journal of Pharmacology [Internet]. 2006;149(3):250–60. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-33749000597&doi=10.1038%252fsj.bjp.0706830&partnerID=40&md5=4ab8bfb364bf170c08277a8d26cb5e00
108.
Sobol E, Yagen B, Steve White H, Wilcox KS, Lamb JG, Pappo O, et al. Preclinical evaluation of 2,2,3,3-tetramethylcyclopropanecarbonyl-urea, a novel, second generation to valproic acid, antiepileptic drug. Neuropharmacology [Internet]. 2006;51(4):933–46. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-33747826028&doi=10.1016%252fj.neuropharm.2006.06.006&partnerID=40&md5=b54eca75cbcddc37af16143dd041d0e5
109.
Okada A, Onishi Y, Aoki Y, Yagen B, Sobol E, Bialer M, et al. Teratology study of derivatives of tetramethylcyclopropyl amide analogues of valproic acid in mice. Birth Defects Research Part B - Developmental and Reproductive Toxicology [Internet]. 2006;77(3):227–33. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-33745460470&doi=10.1002%252fbdrb.20078&partnerID=40&md5=5ddf5f0a060c9c4f8491d16540e3b870
110.
Bialer M. New antiepileptic drugs that are second generation to existing antiepileptic drugs. Expert Opinion on Investigational Drugs [Internet]. 2006;15(6):637–47. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-33745251005&doi=10.1517%252f13543784.15.6.637&partnerID=40&md5=99e5e17098ab77450132cb61e9663354
111.
Bialer M. The pharmacokinetics and interactions of new antiepileptic drugs: An overview. Therapeutic Drug Monitoring [Internet]. 2005;27(6):722–6. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-33646847032&doi=10.1097%252f01.ftd.0000179854.16846.67&partnerID=40&md5=45e81e9a65bc5a85351ff7559452117c
112.
Winkler I, Blotnik S, Shimshoni J, Yagen B, Devor M, Bialer M. Efficacy of antiepileptic isomers of valproic acid and valpromide in a rat model of neuropathic pain. British Journal of Pharmacology [Internet]. 2005;146(2):198–208. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-30544438144&doi=10.1038%252fsj.bjp.0706310&partnerID=40&md5=d89e5d7c12d86864e053d31924b71b29
113.
Winkler I, Sobol E, Yagen B, Steinman A, Devor M, Bialer M. Efficacy of antiepileptic tetramethylcyclopropyl analogues of valproic acid amides in a rat model of neuropathic pain. Neuropharmacology [Internet]. 2005;49(8):1110–20. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-27744565911&doi=10.1016%252fj.neuropharm.2005.06.008&partnerID=40&md5=f5b1f8e961ab7afc43fcea2aab815a3a
114.
Sobol E, Yagen B, Winkler I, Britzi M, Gibson D, Bialer M. Pharmacokinetics and metabolism of a new potent antiepileptic drug, 2,2,3,3-tetramethycyclopropanecarbonylurea, in rats. Drug Metabolism and Disposition [Internet]. 2005;33(10):1538–46. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-24944565232&doi=10.1124%252fdmd.105.005637&partnerID=40&md5=eda95308b728dfb16b506c9f8577b241
115.
Mimrod D, Specchio LM, Britzi M, Perucca E, Specchio N, Neve AL, et al. A comparative study of the effect of carbamazepine and valproic acid on the pharmacokinetics and metabolic profile of topiramate at steady state in patients with epilepsy. Epilepsia [Internet]. 2005;46(7):1046–54. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-21844447569&doi=10.1111%252fj.1528-1167.2005.06805.x&partnerID=40&md5=57732347f4a35e59abee74ae56989b1d
116.
Eyal S, Yagen B, Shimshoni J, Bialer M. Histone deacetylases inhibition and tumor cells cytotoxicity by CNS-active VPA constitutional isomers and derivatives. Biochemical Pharmacology [Internet]. 2005;69(10):1501–8. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-18044381744&doi=10.1016%252fj.bcp.2005.02.012&partnerID=40&md5=ba160a866e8592b9e72f9f281222cb94
117.
Okada A, Kushima K, Aoki Y, Bialer M, Fujiwara M. Identification of early-responsive genes correlated to valproic acid-induced neural tube defects in mice. Birth Defects Research Part A - Clinical and Molecular Teratology [Internet]. 2005;73(4):229–38. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-18144374152&doi=10.1002%252fbdra.20131&partnerID=40&md5=118e8ce28fb370b0d124c37b7ac3e7c6
118.
Britzi M, Perucca E, Soback S, Levy RH, Fattore C, Crema F, et al. Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in the absence and in the presence of enzyme induction by carbamazepine. Epilepsia [Internet]. 2005;46(3):378–84. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-20144373179&doi=10.1111%252fj.0013-9580.2005.55204.x&partnerID=40&md5=e12e45566ea3276d999bb18777409f29
119.
Sobol E, Bialer M. Critical analysis of the discrepancy between Vβ and Vss for drugs exhibiting different two-compartment disposition profiles. Biopharmaceutics and Drug Disposition [Internet]. 2005;26(2):51–8. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-15544363778&doi=10.1002%252fbdd.431&partnerID=40&md5=9af605433902e92a250f07c17828a338
120.
Bialer M. Interactions of antiepileptic drugs. Zhurnal nevrologii i psikhiatrii imeni SS Korsakova / Ministerstvo zdravookhraneniia i meditsinskoi promyshlennosti Rossiiskoi Federatsii, Vserossiiskoe obshchestvo nevrologov [i] Vserossiiskoe obshchestvo psikhiatrov [Internet]. 2005;105(9):59–60. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-33344476056&partnerID=40&md5=2571574fe63baea8f7d35dae53302424
121.
Shank RP, Doose DR, Streeter AJ, Bialer M. Plasma and whole blood pharmacokinetics of topiramate: The role of carbonic anhydrase. Epilepsy Research [Internet]. 2005;63(2–3):103–12. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-17044407601&doi=10.1016%252fj.eplepsyres.2005.01.001&partnerID=40&md5=bb26506fd36e64b62e3d18f058df2b64
122.
Shaltiel G, Shamir A, Shapiro J, Ding D, Dalton E, Bialer M, et al. Valproate decreases inositol biosynthesis. Biological Psychiatry [Internet]. 2004;56(11):868–74. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-9644276924&doi=10.1016%252fj.biopsych.2004.08.027&partnerID=40&md5=93f0cf567abb4328d5fe7f02fcbb38c7
123.
Bialer M, Twyman RE, White HS. Correlation analysis between anticonvulsant ED50 values of antiepileptic drugs in mice and rats and their therapeutic doses and plasma levels. Epilepsy and Behavior [Internet]. 2004;5(6):866–72. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-10844220718&doi=10.1016%252fj.yebeh.2004.08.021&partnerID=40&md5=f1cc924980d7c94fd65c57bd0ab41210
124.
Okada A, Aoki Y, Kushima K, Kurihara H, Bialer M, Fujiwara M. Polycomb homologs are involved in teratogenicity of valproic acid in mice. Birth Defects Research Part A - Clinical and Molecular Teratology [Internet]. 2004;70(11):870–9. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-10044274115&doi=10.1002%252fbdra.20085&partnerID=40&md5=79236f436e5da131246433620b2b93d9
125.
Bialer M, Doose DR, Murthy B, Curtin C, Wang SS, Twyman RE, et al. Pharmacokinetic interactions of topiramate. Clinical Pharmacokinetics [Internet]. 2004;43(12):763–80. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-4644327804&doi=10.2165%252f00003088-200443120-00001&partnerID=40&md5=0aa9b7ad39ad3af99304bf3616bf7d75
126.
Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T. Progress report on new antiepileptic drugs: A summary of the Seventh Eilat Conference (EILAT VII). Epilepsy Research [Internet]. 2004;61(1–3):1–48. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-4644301804&doi=10.1016%252fj.eplepsyres.2004.07.010&partnerID=40&md5=24c94b5998b60bc07cb222f5718831c8
127.
Sobol E, Bialer M, Yagen B. Tetramethylcyclopropyl analogue of a leading antiepileptic drug, valproic acid. Synthesis and evaluation of anticonvulsant activity of its amide derivatives. Journal of Medicinal Chemistry [Internet]. 2004;47(17):4316–26. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-3843141802&doi=10.1021%252fjm0498351&partnerID=40&md5=bb4a62901a8315c60ca2666a3699f502
128.
Eyal S, Yagen B, Sobol E, Altschuler Y, Shmuel M, Bialer M. The activity of antiepileptic drugs as histone deacetylase inhibitors. Epilepsia [Internet]. 2004;45(7):737–44. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-3042859183&doi=10.1111%252fj.0013-9580.2004.00104.x&partnerID=40&md5=09db9b4ea95eb8a24731b9155d276cdc
129.
Sobol E, Bialer M. The relationships between half-life (t1/2) and mean residence time (MRT) in the two-compartment open body model. Biopharmaceutics and Drug Disposition [Internet]. 2004;25(4):157–62. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-2942687180&doi=10.1002%252fbdd.396&partnerID=40&md5=7ac0cfcea573a36626b38b57c7887f77
130.
Gil-Nagel A, Perucca E, García-Morales I, Arroyo S, Serratosa JM, Avanzini G, et al. Evaluations and Awards at the Fifth European Congress of Epileptology, Madrid, 6-10 October 2002. Epilepsia [Internet]. 2004;45(4):396–8. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-11144357472&doi=10.1111%252fj.0013-9580.2004.63903.x&partnerID=40&md5=e6df3340c0efa04bf03474fdd1318023
131.
Sobol E, Bialer M. Mathematical comparison between volume of distribution (V) and volume of distribution at steady-state (VSS) utilizing model-indepent approach. Biopharmaceutics and Drug Disposition [Internet]. 2004;25(2):99–101. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-1842420350&doi=10.1002%252fbdd.372&partnerID=40&md5=f7d2b313a6575a4bd7ffa7270051db1e
132.
Okada A, Kurihara H, Aoki Y, Bialer M, Fujiwara M. Amidic Modification of Valproic Acid Reduces Skeletal Teratogenicity in Mice. Birth Defects Research Part B - Developmental and Reproductive Toxicology [Internet]. 2004;71(1):47–53. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-1542357630&doi=10.1002%252fbdrb.10057&partnerID=40&md5=abb15e6c0d67ea28ee8001fdd1c3719d
133.
Isoherranen N, Levy RH, Yagen B, Woodhead JH, White HS, Bialer M. Metabolism of a new antiepileptic drug, N-methyl- tetramethylcyclopropanecarboxamide, and anticonvulsant activity of its metabolites. Epilepsy Research [Internet]. 2004;58(1):1–12. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-1842556076&doi=10.1016%252fj.eplepsyres.2003.12.001&partnerID=40&md5=184cc9f84962fa58970cada99f7974eb
134.
Isoherranen N, Spiegelstein O, Bialer M, Zhang J, Merriweather M, Yagen B, et al. Developmental Outcome of Levetiracetam, Its Major Metabolite in Humans, 2-Pyrrolidinone N-Butyric Acid, and Its Enantiomer (R)-α -ethyl-oxo-pyrrolidine Acetamide in a Mouse Model of Teratogenicity. Epilepsia [Internet]. 2003;44(10):1280–8. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0142040806&doi=10.1046%252fj.1528-1157.2003.21503.x&partnerID=40&md5=fee458d1a28d20909d7eb8a7c7f9218d
135.
Isoherranen N, White HS, Klein BD, Roeder M, Woodhead JH, Schurig V, et al. Pharmacokinetic-pharmacodynamic relationships of (2S,3S)-valnoctamide and its stereoisomer (2R,3S)-valnoctamide in rodent models of epilepsy. Pharmaceutical Research [Internet]. 2003;20(8):1293–301. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0042125466&doi=10.1023%252fA%253a1025069519218&partnerID=40&md5=2f274515924e90db7f680fb6725ec3ee
136.
Doose DR, Brodie MJ, Wilson EA, Chadwick D, Oxbury J, Berry DJ, et al. Topiramate and lamotrigine pharmacokinetics during repetitive monotherapy and combination therapy in epilepsy patients. Epilepsia [Internet]. 2003;44(7):917–22. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0037816146&doi=10.1046%252fj.1528-1157.2003.64402.x&partnerID=40&md5=2cc280e5acda120e7851e92057699cac
137.
Johannessen SI, Battino D, Berry DJ, Bialer M, Krämer G, Tomson T, et al. Therapeutic drug monitoring of the newer antiepileptic drugs. Therapeutic Drug Monitoring [Internet]. 2003;25(3):347–63. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0038442675&doi=10.1097%252f00007691-200306000-00016&partnerID=40&md5=fb576a7546622ca75ebf7da9993fa286
138.
Britzi M, Soback S, Isoherranen N, Levy RH, Perucca E, Doose DR, et al. Analysis of topiramate and its metabolites in plasma and urine of healthy subjects and patients with epilepsy by use of a novel liquid chromatography-mass spectrometry assay. Therapeutic Drug Monitoring [Internet]. 2003;25(3):314–22. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0038103548&doi=10.1097%252f00007691-200306000-00012&partnerID=40&md5=b56640f044045bced677e6b7ce38d1ec
139.
Isoherranen N, Yagen B, Spiegelstein O, Finnell RH, Merriweather M, Woodhead JH, et al. Anticonvulsant activity, teratogenicity and pharmacokinetics of novel valproyltaurinamide derivatives in mice. British Journal of Pharmacology [Internet]. 2003;139(4):755–64. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0037664485&doi=10.1038%252fsj.bjp.0705301&partnerID=40&md5=0af5e356e481f1487c112811e5311df8
140.
Isoherranen N, Yagen B, Spiegelstein O, Steinman A, Finnell RH, Bialer M. Gas chromatographic determination of novel valproyl taurinamide derivatives in mouse and dog plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences [Internet]. 2003;788(1):125–36. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0037420714&doi=10.1016%2fS1570-0232%2802%2901034-6&partnerID=40&md5=c4ec43a4577104307093ba0cd980cabf
141.
Isoherranen N, Yagen B, Bialer M. New CNS-active drugs which are second-generation valproic acid: Can they lead to the development of a magic bullet? Current Opinion in Neurology [Internet]. 2003;16(2):203–11. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0242499953&doi=10.1097%252f00019052-200304000-00014&partnerID=40&md5=944634f628a9b4595b8031b168a02924
142.
Isoherranen N, Yagen B, Woodhead JH, Spiegelstein O, Blotnik S, Wilcox KS, et al. Characterization of the anticonvulsant profile and enantioselective pharmacokinetics of the chiral valproylamide propylisopropyl acetamide in rodents. British Journal of Pharmacology [Internet]. 2003;138(4):602–13. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0037293556&doi=10.1038%252fsj.bjp.0705076&partnerID=40&md5=044da9bb18486358832aa9e7bedf39d2
143.
Williams J, Bialer M, Johannessen SI, Krämer G, Levy R, Mattson RH, et al. Interlaboratory variability in the quantification of new generation antiepileptic drugs based on external quality assessment data. Epilepsia [Internet]. 2003;44(1):40–5. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0037666055&doi=10.1046%252fj.1528-1157.2003.26702.x&partnerID=40&md5=f5e0e1f620833ed942059b5e460ec98f
144.
Doose DR, Wang SS, Padmanabhan M, Schwabe S, Jacobs D, Bialer M. Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects. Epilepsia [Internet]. 2003;44(4):540–9. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0037529325&doi=10.1046%252fj.1528-1157.2003.55602.x&partnerID=40&md5=45015a4a7e5651f3be75253c6d9f1cfc
145.
Sachdeo RC, Sachdeo SK, Levy RH, Streeter AJ, Bishop FE, Kunze KL, et al. Erratum: Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients (Epilepsia (2002) 43 (691-696)). Epilepsia [Internet]. 2002;43(10):1273. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-18644372354&doi=10.1046%252fj.1528-1157.2002.04310.x&partnerID=40&md5=e8a2ad6556f4c5ccf499159df791b308
146.
Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E. Progress report on new antiepileptic drugs: A summary of the Sixth Eilat Conference (EILAT VI). Epilepsy Research [Internet]. 2002;51(1–2):31–71. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0036752811&doi=10.1016%2fS0920-1211%2802%2900106-7&partnerID=40&md5=d57318ad6907f9719b053e5ea0e9a359
147.
Sachdeo RC, Sachdeo SK, Levy RH, Streeter AJ, Bishop FE, Kunze KL, et al. Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients. Epilepsia [Internet]. 2002;43(7):691–6. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0036069024&doi=10.1046%252fj.1528-1157.2002.41701.x&partnerID=40&md5=fe75556e6aa75e6cca848fd7d0eca1b1
148.
Isoherranen N, White HS, Finnell RH, Yagen B, Woodhead JH, Bennett GD, et al. Anticonvulsant profile and teratogenicity of N-methyl-tetramethylcyclopropyl carboxamide: A new antiepileptic drug. Epilepsia [Internet]. 2002;43(2):115–26. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0036126054&doi=10.1046%252fj.1528-1157.2002.25801.x&partnerID=40&md5=31148c5db47713b50929e40821a88e92
149.
Bialer M. New antiepileptic drugs currently in clinical trials: Is there a strategy in their development? Therapeutic Drug Monitoring [Internet]. 2002;24(1):85–90. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0036146487&doi=10.1097%252f00007691-200202000-00015&partnerID=40&md5=033ba1c44a336df11c1383ef340a6e36
150.
Bialer M, Walker MC, Sander JW. Pros and cons for the development of new antiepileptic drugs. CNS Drugs [Internet]. 2002;16(5):285–9. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0036100537&doi=10.2165%252f00023210-200216050-00001&partnerID=40&md5=1a63dd8b990438e22bf91dbc8557ca75
151.
Isoherranen N, Yagen B, Soback S, Roeder M, Schurig V, Bialer M. Pharmacokinetics of levetiracetam and its enantiomer (R)-α-ethyl-2-oxo-pyrrolidine acetamide in dogs. Epilepsia [Internet]. 2001;42(7):825–30. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0034849129&doi=10.1046%252fj.1528-1157.2001.042007825.x&partnerID=40&md5=ba2c405ac82dce75c543cff7e77c4272
152.
Isherranen N, Woodhead JH, Steve White H, Bialer M. Anticonvulsant profile of valrocemide (TV1901): A new antiepileptic drug. Epilepsia [Internet]. 2001;42(7):831–6. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0034844676&doi=10.1046%252fj.1528-1157.2001.042007831.x&partnerID=40&md5=b4b41acbbac2dbd541ef531f23d2e077
153.
Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E. Progress report on new antiepileptic drugs: A summary of the Fifth Eilat Conference (EILAT V). Epilepsy Research [Internet]. 2001;43(1):11–58. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0035200133&doi=10.1016%2fS0920-1211%2800%2900171-6&partnerID=40&md5=56e83b0f2b488040ed9ec3a9b1c8b206
154.
Wasserman M, Yagen B, Blotnik S, Papo N, Bialer M. Stereoselective pharmacokinetic analysis and antiepileptic activity of n-2-hydroxypropyl valpromide, a central nervous system-active chiral valproylamide. Therapeutic Drug Monitoring [Internet]. 2001;23(4):414–20. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0034902426&doi=10.1097%252f00007691-200108000-00016&partnerID=40&md5=00437fb9e9061eb96ef1a2b141a07e7a
155.
Spiegelstein O, Yagen B, Bennett GD, Finnell RH, Blotnik S, Bialer M. Stereoselective pharmacokinetic analysis of valnoctamide, a CNS-active chiral amide analogue of valproic acid, in dogs, rats, and mice. Therapeutic Drug Monitoring [Internet]. 2000;22(5):574–81. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0033807214&doi=10.1097%252f00007691-200010000-00012&partnerID=40&md5=16fda888a9f6d3eeefcb4f47322f9c96
156.
Britzi M, Bialer M, Arcavi L, Shachbari A, Kapitulnik J, Soback S. Genetic polymorphism of CYP2D6 and CYP2C19 metabolism determined by phenotyping Israeli ethnic groups. Therapeutic Drug Monitoring [Internet]. 2000;22(5):510–6. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0033802124&doi=10.1097%252f00007691-200010000-00002&partnerID=40&md5=195dabe13e7e0eed4955dc0669e7732e
157.
Isoherranen N, Roeder M, Soback S, Yagen B, Schurig V, Bialer M. Enantioselective analysis of levetiracetam and its enantiomer R-α- ethyl-2-oxo-pyrrolidine acetamide using gas chromatography and ion trap mass spectrometric detection. Journal of Chromatography B: Biomedical Sciences and Applications [Internet]. 2000;745(2):325–32. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0034683005&doi=10.1016%2fS0378-4347%2800%2900293-0&partnerID=40&md5=f58fb565f6505d1cc9fa39109f7dc453
158.
Spiegelstein O, Kroetz DL, Levy RH, Yagen B, Hurst SI, Levi M, et al. Structure activity relationship of human microsomal epoxide hydrolase inhibition by amide and acid analogues of valproic acid. Pharmaceutical Research [Internet]. 2000;17(2):216–21. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0034059186&doi=10.1023%252fA%253a1007577600088&partnerID=40&md5=f39e98763b2c8c5ea929205c7785b46a
159.
Volosov A, Bialer M, Xiaodong S, Perucca E, Sintov A, Yagen B. Simultaneous stereoselective high-performance liquid chromatographic determination of 10-hydroxycarbazepine and its metabolite carbamazepine- 10,11-trans-dihydrodiol in human urine. Journal of Chromatography B: Biomedical Sciences and Applications [Internet]. 2000;738(2):419–25. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0033974458&doi=10.1016%2fS0378-4347%2899%2900531-9&partnerID=40&md5=03c0b73e496675d1f285380f63ec466b
160.
Lindekens H, Smolders I, Khan GM, Bialer M, Ebinger G, Michotte Y. In vivo study of the effect of valpromide and valnoctamide in the pilocarpine rat model of focal epilepsy. Pharmaceutical Research [Internet]. 2000;17(11):1408–13. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0034492526&doi=10.1023%252fA%253a1007559208599&partnerID=40&md5=e7f47d21c5a4f247cdb686012e3f9618
161.
Volosov A, Yagen B, Bialer M. Comparative stereoselective pharmacokinetic analysis of 10-hydroxycarbazepine after oral administration of its individual enantiomers and the racemic mixture to dogs. Epilepsia [Internet]. 2000;41(9):1107–11. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0033821719&doi=10.1111%252fj.1528-1157.2000.tb00315.x&partnerID=40&md5=89f138826f66b31a6ed7c72b3cd5f567
162.
Spiegelstein O, Yagen B, Levy RH, Finnell RH, Bennett GD, Roeder M, et al. Stereoselective pharmacokinetics and pharmacodynamics of propylisopropyl acetamide, a CNS-active chiral amide analog of valproic acid. Pharmaceutical Research [Internet]. 1999;16(10):1582–8. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0012677096&doi=10.1023%252fA%253a1018960722284&partnerID=40&md5=9527db7ef80cffc71b5dc9b5893c109a
163.
Bialer M. Pharmacokinetic considerations in the design of better and safer new antiepileptic drugs. Journal of Controlled Release [Internet]. 1999;62(1–2):187–92. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0032863679&doi=10.1016%2fS0168-3659%2899%2900037-1&partnerID=40&md5=dab4a2a9afb64bea676a392640cac511
164.
Spiegelstein O, Bialer M, Radatz M, Nau H, Yagen B. Enantioselective synthesis and teratogenicity of propylisopropyl acetamide, a CNS-active chiral amide analogue of valproic acid. Chirality [Internet]. 1999;11(8):645–50. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0032832441&doi=10.1002%2f%28SICI%291520-636X%281999%2911%3a8%3c645%3a%3aAID-CHIR6%3e3.0.CO%3b2-7&partnerID=40&md5=fcd841112b2ea890c619dee30dc9cf8d
165.
Sussan S, Dagan A, Blotnik S, Bialer M. The structural requirements for the design of antiepileptic-glycine derivatives. Epilepsy Research [Internet]. 1999;34(2–3):207–20. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0032917693&doi=10.1016%2fS0920-1211%2898%2900115-6&partnerID=40&md5=c4ceb0d34b47bc2e12227fd2adcb9481
166.
Volosov A, Sintov A, Bialer M. Stereoselective pharmacokinetic analysis of the antiepileptic 10- hydroxycarbazepine in dogs. Therapeutic Drug Monitoring [Internet]. 1999;21(2):219–23. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0032898388&doi=10.1097%252f00007691-199904000-00013&partnerID=40&md5=ab9239cc1bf8e095de3c5a25eb9e4d1d
167.
Roeder M, Spiegelstein O, Schurig V, Bialer M, Yagen B. Absolute configuration of the four stereoisomers of valnoctamide (2- ethyl-3-methyl valeramide), a potentially new stereospecific antiepileptic and CNS drug. Tetrahedron Asymmetry [Internet]. 1999;10(5):841–53. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0033548363&doi=10.1016%2fS0957-4166%2899%2900047-6&partnerID=40&md5=d73c980fede868fc0f2ee824958204a4
168.
Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E. Progress report on new antiepileptic drugs: A summary of The Fourth Eilat Conference (EILAT IV). Epilepsy Research [Internet]. 1999;34(1):1–41. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0033061573&doi=10.1016%2fS0920-1211%2898%2900108-9&partnerID=40&md5=b0eeb8e392bab86a25d553fb5f35c5f7
169.
Volosov A, Bialer M. Use of mean residence time to determine the magnitude of difference between rate constants and to calculate t(max) in the Bateman equation. Biopharmaceutics and Drug Disposition [Internet]. 1999;20(1):3–9. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0032924495&doi=10.1002%2f%28SICI%291099-081X%28199901%2920%3a1%3c3%3a%3aAID-BDD146%3e3.0.CO%3b2-7&partnerID=40&md5=fe8c6985223666ec825b1231dfcbb031
170.
Volosov A, Xiaodong S, Perucca E, Yagen B, Sintov A, Bialer M. Enantioselective pharmacokinetics of 10-hydroxycarbazepine after oral administration of oxcarbazepine to healthy Chinese subjects. Clinical Pharmacology and Therapeutics [Internet]. 1999;66(6):547–53. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0033391871&doi=10.1053%252fcp.1999.v66.103170001&partnerID=40&md5=c220ce9b0e3e97888f634f653848fd50
171.
Sussan S, Dagan A, Bialer M. Pharmacokinetic analysis and anticonvulsant activity of glycine and glycinamide derivatives. Epilepsy Research [Internet]. 1999;33(1):11–21. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0032993714&doi=10.1016%2fS0920-1211%2898%2900076-X&partnerID=40&md5=bd96badfc1d4b78cf61484894d463fc8
172.
Spiegelstein O, Yagen B, Bialer M. Structure-pharmacokinetic-pharmacodynamic relationships of N-alkyl derivatives of the new antiepileptic drug valproyl glycinamide. Epilepsia [Internet]. 1999;40(5):545–52. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0032890766&doi=10.1111%252fj.1528-1157.1999.tb05555.x&partnerID=40&md5=4b0e4dfb4ee6fecd57eea76ea0a29ea4
173.
Bialer M, Arcavi L, Sussan S, Volosov A, Yacobi A, Moros D, et al. Existing and new criteria for bioequivalence evaluation of new controlled release (CR) products of carbamazepine. Epilepsy Research [Internet]. 1998;32(3):371–8. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0031741910&doi=10.1016%2fS0920-1211%2898%2900064-3&partnerID=40&md5=66caa2e1d3cfc70ce06fdb7d8c778e66
174.
Bialer M, Yacobi A, Moros D, Levitt B, Houle JM, Munsaka MS. Criteria to assess in vivo performance and bioequivalence of generic controlled-release formulations of carbamazepine. Epilepsia [Internet]. 1998;39(5):513–9. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0031898134&doi=10.1111%252fj.1528-1157.1998.tb01414.x&partnerID=40&md5=417bd50136d0e70e6a7cbc0d1e71ab41
175.
Blotnik S, Bergman F, Bialer M. Disposition of two tetramethylcyclopropane analogues of valpromide in the brain, liver, plasma and urine of rats. European Journal of Pharmaceutical Sciences [Internet]. 1998;6(2):93–8. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0032055565&doi=10.1016%2fS0928-0987%2897%2900081-X&partnerID=40&md5=a5fb27021b6633edc245a602731c980c
176.
Radatz M, Ehlers K, Yagen B, Bialer M, Nau H. Valnoctamide, valpromide and valnoctic acid are much less teratogenic in mice than valproic acid. Epilepsy Research [Internet]. 1998;30(1):41–8. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0031912815&doi=10.1016%2fS0920-1211%2897%2900095-8&partnerID=40&md5=be3669545a6912f26d7d7a93f868fd37
177.
Bialer M, Levy RH, Perucca E. Does carbamazepine have a narrow therapeutic plasma concentration range? Therapeutic Drug Monitoring [Internet]. 1998;20(1):56–9. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0031935126&doi=10.1097%252f00007691-199802000-00010&partnerID=40&md5=a9139624ae4273500b9c58d3f9ab8674
178.
Hadad S, Bialer M. Pharmacokinetic analysis and antiepileptic activity of two new isomers of N-valproyl glycinamide. Biopharmaceutics and Drug Disposition [Internet]. 1997;18(7):557–66. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0030819103&doi=10.1002%2f%28SICI%291099-081X%28199710%2918%3a7%3c557%3a%3aAID-BDD48%3e3.0.CO%3b2-D&partnerID=40&md5=e1e52f0ff4c3df6b360a3f4d333bd2ce
179.
Spiegelstein O, Bialer M, Yagen B. Isolation of N,N-dialkylated derivatives of valproylglycinamide from dog plasma by active charcoal adsorption and their quantification by high-performance liquid chromatography. Journal of Chromatography B: Biomedical Applications [Internet]. 1997;698(1–2):195–200. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0030804122&doi=10.1016%2fS0378-4347%2897%2900269-7&partnerID=40&md5=86d7f07ca176d6be0ac0b18d7daf1d27
180.
Blotnik S, Bergman F, Bialer M. The disposition of valproyl glycinamide and valproyl glycine in rats. Pharmaceutical Research [Internet]. 1997;14(7):873–8. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0030849279&doi=10.1023%252fA%253a1012143631873&partnerID=40&md5=a6bec4e81cc76df9e55d9dfad5a3bb77
181.
Levi M, Yagen B, Bialer M. Pharmacokinetics and antiepileptic activity of valproyl hydroxamic acid derivatives. Pharmaceutical Research [Internet]. 1997;14(2):213–7. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0031004264&doi=10.1023%252fA%253a1012009012850&partnerID=40&md5=acef5b02d41777c586b5a8bd74cd47ce
182.
Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E. Erratum: Corrigendum to: “Conference report. Progress report on new antiepileptic drugs: A summary of the Third Eilat Conference” [Epilepsy Res. 25 (1996) 299] (S0920121196000812). Epilepsy Research [Internet]. 1997;26(3):465. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0030910363&doi=10.1016%2fS0920-1211%2896%2901016-9&partnerID=40&md5=f2f42327d77ed404ebd77ca2d5c05a40
183.
Barel S, Yagen B, Schurig V, Soback S, Pisani F, Perucca E, et al. Stereoselective pharmacokinetic analysis of valnoctamide in healthy subjects and in patients with epilepsy. Clinical Pharmacology and Therapeutics [Internet]. 1997;61(4):442–9. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0030907689&doi=10.1016%2fS0009-9236%2897%2990194-6&partnerID=40&md5=182cf9fa9e800c27655596d65cde4f22
184.
Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E. Progress report on new antiepileptic drugs: A summary of the Third Eilat Conference. Epilepsy Research [Internet]. 1996;25(3):299–319. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0030297333&doi=10.1016%2fS0920-1211%2896%2900081-2&partnerID=40&md5=4d389681be6ec03983ea8e707dc47c13
185.
Bialer M, Kadry B, Abdul-Hai A, Haj-Yehia A, Sterling J, Herzig Y, et al. Pharmacokinetic and pharmacodynamic analysis of (E)-2-ene valproyl derivatives of glycine and valproyl derivatives of nipecotic acid. Biopharmaceutics and Drug Disposition [Internet]. 1996;17(7):565–75. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0029766213&doi=10.1002%2f%28SICI%291099-081X%28199610%2917%3a7%3c565%3a%3aAID-BDD979%3e3.0.CO%3b2-I&partnerID=40&md5=57e273674be3bad22df17a76c78e9bff
186.
Blotnik S, Bergman F, Bialer M. Disposition of valpromide, valproic acid, and valnoctamide in the brain, liver, plasma, and urine of rats. Drug Metabolism and Disposition [Internet]. 1996;24(5):560–4. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0029979326&partnerID=40&md5=eff6dc3a730cb77a8fca759b1ce9538f
187.
Bialer M, Hadad S, Kadry B, Abdul-Hai A, Haj-Yehia A, Sterling J, et al. Pharmacokinetic Analysis and Antiepileptic Activity of Tetra-Methylcyclopropane Analogues of Valpromide. Pharmaceutical Research [Internet]. 1996;13(2):284–9. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0030052508&doi=10.1023%252fA%253a1016055517724&partnerID=40&md5=57699f9252f4c8552b84901938284ea1
188.
Perucca E, Bialer M. The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine. Clinical Pharmacokinetics [Internet]. 1996;31(1):29–46. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0029887507&doi=10.2165%252f00003088-199631010-00003&partnerID=40&md5=525d5b86d176698f5b23ef79f3d17458
189.
Hadad S, Bialer M. Pharmacokinetic Analysis and Antiepileptic Activity of N-Valproyl Derivatives of GABA and Glycine. Pharmaceutical Research: An Official Journal of the American Association of Pharmaceutical Scientists [Internet]. 1995;12(6):905–10. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0029020746&doi=10.1023%252fA%253a1016277507865&partnerID=40&md5=d9cbf23f6d11cd61266e1d36da3a9114
190.
Samara E, Avnir D, Ladkani D, Bialer M. Pharmacokinetic analysis of diethylcarbonate prodrugs of ibuprofen and naproxen. Biopharmaceutics & Drug Disposition [Internet]. 1995;16(3):201–10. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0028961924&doi=10.1002%252fbdd.2510160305&partnerID=40&md5=69607060c20a9470024cfa5f0cd39c62
191.
Bialer M, Sussan S, Salach OA, Danenberg HD, Ben‐David J, Gibor Y, et al. Criteria to assess in vivo performance of sustained release products: Application to diltiazem formulations. Journal of Pharmaceutical Sciences [Internet]. 1995;84(10):1160–3. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0028862734&doi=10.1002%252fjps.2600841005&partnerID=40&md5=9462913a03e23bc0a19ca6d75d423d9b
192.
Stables JP, Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, et al. Progress report on new antiepileptic drugs A summary of the Second Eilat Conference. Epilepsy Research [Internet]. 1995;22(3):235–46. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0028860734&doi=10.1016%2f0920-1211%2895%2900054-2&partnerID=40&md5=1751382fd7a12f0872867ff0b368338b
193.
Abu Salach O, Hadad S, Haj-Yehia A, Sussan S, Bialer M. FC27 comparative pharmacokinetic and pharmacodynamic analysis of phthaloyl glycine derivatives with potential antiepileptic activity. European Journal of Pharmaceutical Sciences [Internet]. 1994;2(1–2):107. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-43949159338&doi=10.1016%2f0928-0987%2894%2990136-8&partnerID=40&md5=f4bb4577a34c2b165f5d87ad71cd5d21
194.
Bialer M, Haj-Yehia A, Badir K, Hadad S. Can we develop improved derivatives of valproic acid? Pharmacy World & Science [Internet]. 1994;16(1):2–6. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0028353534&doi=10.1007%252fBF01870931&partnerID=40&md5=00d4da6b2d176c0fce588e1922e00b1e
195.
Bialer M, Pharaj Z, Zuckerman S, Raz I, Abramsky O, Sterling J, et al. Pharmacokinetic analysis of valdice - a diethylcarbonate prodrug of valproic acid. European Journal of Pharmaceutical Sciences [Internet]. 1994;2(3):239–44. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0028152556&doi=10.1016%2f0928-0987%2894%2990028-0&partnerID=40&md5=b9287e1e8020aa134a33e29f49be2e7e
196.
Barel S, Yagen B, Bialer M. Pharmacokinetic profile of conjugated verrucarol urinary metabolites in dogs. Biopharmaceutics & Drug Disposition [Internet]. 1994;15(7):609–16. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0028106039&doi=10.1002%252fbdd.2510150708&partnerID=40&md5=95f09b1ede9b1b991b0deb359c95a10b
197.
Perucca E, Gatti G, Cipolla G, Spina E, Barel S, Soback S, et al. Inhibition of diazepam metabolism by fluvoxamine: A pharmacokinetic study in normal volunteers. Clinical Pharmacology & Therapeutics [Internet]. 1994;56(5):471–6. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0028080304&doi=10.1038%252fclpt.1994.167&partnerID=40&md5=607985fd3d2c8679911dcfd13fc54b70
198.
Bialer M, Hadad S, Golomb G, Barel S, Samara E, Salach OA, et al. Pharmacokinetic analysis of two new sustained‐release products of diltiazem designed for twice‐and once‐daily treatment. Biopharmaceutics & Drug Disposition [Internet]. 1994;15(1):45–52. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0028053169&doi=10.1002%252fbdd.2510150104&partnerID=40&md5=9539d7c01955580b55054583f239bc5c
199.
Soback S, Gips M, Bialer M, Bor A. Effect of lactation on single-dose pharmacokinetics of norfloxacin nicotinate in ewes. Antimicrobial Agents and Chemotherapy [Internet]. 1994;38(10):2336–9. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0028016329&doi=10.1128%252fAAC.38.10.2336&partnerID=40&md5=b8739ae6f710323ba090d189f15e6da2
200.
Salach OA, Hadad S, Haj-Yehia A, Sussan S, Bialer M. Comparative Pharmacokinetic and Pharmacodynamic Analysis of Phthaloyl Glycine Derivatives with Potential Antiepileptic Activity. Pharmaceutical Research: An Official Journal of the American Association of Pharmaceutical Scientists [Internet]. 1994;11(10):1429–34. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0027997005&doi=10.1023%252fA%253a1018943906510&partnerID=40&md5=5f3ee114e3b7cb61cee6e4ac4b993453
201.
Pisani F, Haj-Yehia A, Fazio A, Artesi C, Oteri G, Perucca E, et al. Interaction of Carbamazepine with Valnoctamide: Data “in vitro” and in patients with epilepsy [INTERAZIONE DELLA CARBAMAZEPINA CON LA VALNOCTAMIDE: DATI “IN VITRO” ED IN PAZIENTI CON EPILESSIA]. Bollettino - Lega Italiana contro l’Epilessia [Internet]. 1993;(82–83):159. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0027819686&partnerID=40&md5=def0dde2e4470a4fe7041f2f57587cda
202.
Hadad S, Vree TB, Van Der Kleijn E, Bialer M. Pharmacokinetic analysis and anticonvulsant activity of two polyesteric prodrugs of valproic acid. Biopharmaceutics & Drug Disposition [Internet]. 1993;14(1):51–9. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0027507342&doi=10.1002%252fbdd.2510140105&partnerID=40&md5=49bd5d0b984fcb2639be1c13efa8c981
203.
Yagen B, Bialer M. Metabolism and pharmacokinetics of t-2 toxin and related trichothecenes. Drug Metabolism Reviews [Internet]. 1993;25(3):281–323. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0027244640&doi=10.3109%252f03602539308993978&partnerID=40&md5=011ff562a19ac4bca01fd1f92f426004
204.
Bialer M. Comparative Pharmacokinetics of the Newer Antiepileptic Drugs. Clinical Pharmacokinetics [Internet]. 1993;24(6):441–52. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0027223706&doi=10.2165%252f00003088-199324060-00002&partnerID=40&md5=d0968912814de9d4e529ec740e2916d7
205.
Gabizon AA, Barenholz Y, Bialer M. Prolongation of the Circulation Time of Doxorubicin Encapsulated in Liposomes Containing a Polyethylene Glycol-Derivatized Phospholipid: Pharmacokinetic Studies in Rodents and Dogs. Pharmaceutical Research: An Official Journal of the American Association of Pharmaceutical Scientists [Internet]. 1993;10(5):703–8. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0027162899&doi=10.1023%252fA%253a1018907715905&partnerID=40&md5=2ef02708b86d5c9830194235888b33a4
206.
Hadad S, Vree TB, Kleijn EVD, Bialer M. Pharmacokinetic analysis of ester prodrugs of valproic acid. Journal of Pharmaceutical Sciences [Internet]. 1992;81(10):1047–50. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0027087343&doi=10.1002%252fjps.2600811019&partnerID=40&md5=dccc58dd8b6c3a7521eed0e19bc9c9f0
207.
Haj-Yehia A, Hadad S, Bialer M. Pharmacokinetic Analysis of the Structural Requirements for Forming “Stable” Analogues of Valpromide. Pharmaceutical Research: An Official Journal of the American Association of Pharmaceutical Scientists [Internet]. 1992;9(8):1058–63. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0026733527&doi=10.1023%252fA%253a1015862613315&partnerID=40&md5=6216f5c4d968005252d19ac7b60dfaf5
208.
Bialer M. Pharmacokinetic Evaluation of Sustained Release Formulations of Antiepileptic Drugs: Clinical Implications. Clinical Pharmacokinetics [Internet]. 1992;22(1):11–21. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0026584229&doi=10.2165%252f00003088-199222010-00002&partnerID=40&md5=485003596acd016d94e6eed7a6b1bd39
209.
Samara E, Bialer M, Harvey DJ. Metabolism of cannabidiol by the rat. European Journal of Drug Metabolism and Pharmacokinetics [Internet]. 1991;16(4):305–13. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0026353540&doi=10.1007%252fBF03189976&partnerID=40&md5=97e9f47028ba602aa14ec8960edfc640
210.
Betlach CJ, Straughn AB, Meyer MC, Bialer M, Vashi VI, Lieberman P, et al. The Effect of Raising Gastric pH with Ranitidine on the Absorption and Elimination of Theophylline from a Sustained-Release Theophylline Tablet. Pharmaceutical Research: An Official Journal of the American Association of Pharmaceutical Scientists [Internet]. 1991;8(12):1516–9. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0026060479&doi=10.1023%252fA%253a1015846417085&partnerID=40&md5=d656b9c62f2e594abee812bdb4a4cbff
211.
Bialer M. Clinical Pharmacology of Valpromide. Clinical Pharmacokinetics [Internet]. 1991;20(2):114–22. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0026015881&doi=10.2165%252f00003088-199120020-00003&partnerID=40&md5=9453e47a1895b5f0471605f050ddab61
212.
Badir K, Haj-Yehia A, Vree TB, van der Kleijn E, Bialer M. Pharmacokinetics and Anticonvulsant Activity of Three Monoesteric Prodrugs of Valproic Acid. Pharmaceutical Research: An Official Journal of the American Association of Pharmaceutical Scientists [Internet]. 1991;8(6):750–3. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0025774314&doi=10.1023%252fA%253a1015854118110&partnerID=40&md5=9b1c2935d1e039f826cd56deee199434
213.
McLean AM, Cefali EA, Roden JS, Gonzalez MA, Bialer M. Stability of diltiazem in different biological fluids. Biopharmaceutics & Drug Disposition [Internet]. 1991;12(5):327–34. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0025755552&doi=10.1002%252fbdd.2510120502&partnerID=40&md5=46f7b3e98cdf62622059ef3b05ca7263
214.
Samara E, Bialer M, Harvey DJ. Identification of urinary metabolites of cannabidiol in the dog. Drug Metabolism and Disposition [Internet]. 1990;18(5):571–9. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0025037461&partnerID=40&md5=3cf6e283203361fca1feeae9a510ca31
215.
Billig H, Ziv E, Bar-on H, Bialer M. The disposition of valpromide in rats and the isolated perfused rat liver. Drug Metabolism and Disposition [Internet]. 1990;18(2):238–44. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0025248831&partnerID=40&md5=d8b816852d37efdcbc2e302ba5183d58
216.
Bialer M, Haj-Yehia A, Barzaghi N, Pisani F, Perucca E. Pharmacokinetics of a valpromide isomer, valnoctamide, in healthy subjects. European Journal of Clinical Pharmacology [Internet]. 1990;38(3):289–91. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0025262283&doi=10.1007%252fBF00315032&partnerID=40&md5=ad2d7ad6d76002aab9fe7796f1a85341
217.
Samara E, Bialer M, Harvey DJ. Pharmacokinetics of urinary metabolites of cannabidiol in the dog. Biopharmaceutics & Drug Disposition [Internet]. 1990;11(9):785–95. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0025642492&doi=10.1002%252fbdd.2510110906&partnerID=40&md5=eaf68816ef19d84974e9f80d15ebbea7
218.
Barel S, Yagen B, Bialer M. Pharmacokinetics of the trichothecene mycotoxin verrucarol in dogs. Journal of Pharmaceutical Sciences [Internet]. 1990;79(6):548–51. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0025375666&doi=10.1002%252fjps.2600790619&partnerID=40&md5=dc6bff26f5d3dc4cafcc57e22f347180
219.
Samara E, Bialer M, Bar-On H, Harvey DJ. Identification of metabolites of the 1’1’dimethylheptyl analogue of cannabidiol in rat and dog in viv. Xenobiotica [Internet]. 1990;20(5):447–55. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0025317694&doi=10.3109%252f00498259009046860&partnerID=40&md5=264f9dfeb117f63b915cb0abb6397c68
220.
McLean AM, Ruggirello DA, Banfield C, Gonzalez MA, Bialer M. Application of a variance‐stabilizing transformation approach to linear regression of calibration lines. Journal of Pharmaceutical Sciences [Internet]. 1990;79(11):1005–8. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0025185223&doi=10.1002%252fjps.2600791112&partnerID=40&md5=7ded4be0f11938aed3c2ab982b8ccbc9
221.
Samara E, Bialer M, Harvey DJ. Identification of glucose conjugates as major urinary metabolites of cannabidiol in the dog. Xenobiotica [Internet]. 1990;20(2):177–83. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0025093518&doi=10.3109%252f00498259009047153&partnerID=40&md5=c3e361cd68ed937ece4a3d5b3b2273fe
222.
Haj‐Yehia A, Bialer M. Structure–pharmacokinetic relationships in a series of short fatty acid amides that possess anticonvulsant activity. Journal of Pharmaceutical Sciences [Internet]. 1990;79(8):719–24. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0025090893&doi=10.1002%252fjps.2600790814&partnerID=40&md5=ed583598836d1cecaf975bff8a64ff09
223.
Haj-Yehia A, Bialer M. Structure–Pharmacokinetic Relationships in a Series of Valpromide Derivatives with Antiepileptic Activity. Pharmaceutical Research: An Official Journal of the American Association of Pharmaceutical Scientists [Internet]. 1989;6(8):683–9. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0024440860&doi=10.1023%252fA%253a1015934321764&partnerID=40&md5=b546dd395c804d1b4ceffc04e28693d2
224.
David JB, Bialer M. Pharmacokinetic interaction between diltiazem and amiodarone in the dog. Biopharmaceutics & Drug Disposition [Internet]. 1989;10(4):423–9. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0024371932&doi=10.1002%252fbdd.2510100409&partnerID=40&md5=c6f6c7c04430a9ea522cab227b95f75f
225.
Mason EJ, Bialer M. The logical structure and validity of experimental designs in pharmacokinetics and clinical pharmacology. Biopharmaceutics & Drug Disposition [Internet]. 1989;10(4):331–51. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0024340154&doi=10.1002%252fbdd.2510100402&partnerID=40&md5=bdd6b1cec876d5fed53c9aff6c4976dd
226.
Samara E, Bialer M. Pharmacokinetics of the dimethylheptyl homolog of cannabidiol in dogs. Drug Metabolism and Disposition [Internet]. 1988;16(6):875–9. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0024230381&partnerID=40&md5=a762871bcedae5ac6b9d1c8631a0ca10
227.
Maislos M, Bialer M, Mead PM, Robbins DC. Pharmacokinetic model of circulating covalent aggregates of insulin. Diabetes [Internet]. 1988;37(8):1059–63. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0024272459&doi=10.2337%252fdiab.37.8.1059&partnerID=40&md5=5f89bab4a8e3727e9058f878a9547e2f
228.
Haj‐Yehia A, Bialer M. Pharmacokinetics of a valpromide isomer, valnoctamide, in dogs. Journal of Pharmaceutical Sciences [Internet]. 1988;77(10):831–4. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0024266719&doi=10.1002%252fjps.2600771003&partnerID=40&md5=b627e9a0dad42d74f8dcd3fa2ce52995
229.
Sintov A, Bialer M, Yagen B. Pharmacokinetics and protein binding of trichothecene mycotoxins, T-2 toxin and HT-2 toxin, in dogs. Toxicon [Internet]. 1988;26(2):153–60. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0023905275&doi=10.1016%2f0041-0101%2888%2990167-5&partnerID=40&md5=14b60a2cfb52b1cfe5ce63ae428c8324
230.
Samara E, Bialer M, Mechoulam R. Pharmacokinetics of cannabidiol in dogs. Drug Metabolism and Disposition [Internet]. 1988;16(3):469–72. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0023877617&partnerID=40&md5=ae2d69ba6f0fba456e47631603ffca16
231.
Bialer M, Wu WH, Faulkner RD, Michael Silber B, Yacobi A. In vitro protein binding interaction studies involving cefixime. Biopharmaceutics & Drug Disposition [Internet]. 1988;9(3):315–20. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0023876849&doi=10.1002%252fbod.2510090309&partnerID=40&md5=3e84c1276c96464279f976385d4a31c9
232.
Bialer M, Wu WH, Look ZM, Silber BM, Yacobi A. Pharmacokinetics of cefixime after oral and intravenous doses in dogs: Bioavailability assessment for a drug showing nonlinear serum protein binding. Research Communications in Chemical Pathology and Pharmacology [Internet]. 1987;56(1):21–32. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0023251421&partnerID=40&md5=adc30f32f5cea698b252980c3e64464d
233.
Sintov A, Bialer M, Yagen B. Pharmacokinetics of t-2 tetraol, a urinary metabolite of the trichothecene mycotoxin, t-2 toxin, in dog. Xenobiotica [Internet]. 1987;17(8):941–50. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0023281007&doi=10.3109%252f00498258709044192&partnerID=40&md5=1b84ba16369ee8096564075b03582acf
234.
Samara E, Bialer M. Rapid high-performance liquid chromatographic assay with pharmacokinetic applications for monitoring cannabidiol in plasma. Journal of Chromatography B: Biomedical Sciences and Applications [Internet]. 1987;416(C):370–4. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0023273717&doi=10.1016%2f0378-4347%2887%2980522-4&partnerID=40&md5=889a18bd132bf6a66ddfc6009aa5fb06
235.
Hussein Z, Bialer M, Friedman M, Raz I. Pharmacokinetic analysis of sustained‐release dosage forms of theophylline in humans: Comparison of single and multiple dose studies. Biopharmaceutics & Drug Disposition [Internet]. 1987;8(5):427–35. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0023267777&doi=10.1002%252fbdd.2510080503&partnerID=40&md5=d1ce3679f06b79fe387fe51f185949cc
236.
Hussein Z, Bialer M, Friedman M, Raz I. Comparative pharmacokinetic evaluation of sustained-release theophylline formulations in dogs and humans. International Journal of Pharmaceutics [Internet]. 1987;37(1–2):97–102. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0023194471&doi=10.1016%2f0378-5173%2887%2990013-5&partnerID=40&md5=ccd5f81f383c0d41977e7719cf03936a
237.
Bialer M, Batra VK, Morrison JA, Silber BM, Look ZM, Yacobi A. Dose-Dependent Pharmacokinetics of a New Oral Cephalosporin, Cefixime, in the Dog. Pharmaceutical Research: An Official Journal of the American Association of Pharmaceutical Scientists [Internet]. 1987;4(1):33–7. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0023112504&doi=10.1023%252fA%253a1016473709720&partnerID=40&md5=14d74e12930af1c4f5894bf0d6a1a410
238.
Tonelli AP, Bialer M, Look ZM, Carson S, Yacobi A. Saturable Processes Affecting Renal Clearance of Cefixime in Dogs. Pharmaceutical Research: An Official Journal of the American Association of Pharmaceutical Scientists [Internet]. 1986;3(3):150–5. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0023028787&doi=10.1023%252fA%253a1016309923717&partnerID=40&md5=8c2d1f8fff021d8b99438a7bdd74e4a3
239.
Rubinstein A, Bialer M, Friedman M, Raz I, Abramsky O. A combined approach to control valproic acid release via novel delivery system of valpromide: A kinetic and pharmacokinetic study. Journal of Controlled Release [Internet]. 1986;4(1):33–8. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0022919305&doi=10.1016%2f0168-3659%2886%2990031-3&partnerID=40&md5=21254980aa13ff758edf191b7c24afbe
240.
Bialer M, Look ZM, Silber BM, Yacobi A. The relationship between drug input and mean residence time in the body. Biopharmaceutics & Drug Disposition [Internet]. 1986;7(6):577–83. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0022903502&doi=10.1002%252fbdd.2510070607&partnerID=40&md5=53e9bd519e54da023ac8b97797e61baf
241.
Pei Y ‐Y., Bialer M, Levy RH. Effects of phenobarbital steady state levels on antipyrine clearance and distribution in the rat. Biopharmaceutics & Drug Disposition [Internet]. 1986;7(1):11–9. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0022651437&doi=10.1002%252fbdd.2510070103&partnerID=40&md5=469b0d3f522c0adfe8acbd180f809f34
242.
Sintov A, Bialer M, Yagen B. Pharmacokinetics of T-2 toxin and its metabolite HT-2 toxin, after intravenous adminstration in dogs. Drug Metabolism and Disposition [Internet]. 1986;14(2):250–4. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0022642440&partnerID=40&md5=3635920361a278a28922b9d77107ecc3
243.
Bialer M, Tonelli AP, Kantrowitz JD, Yacobi A. Serum protein binding of a new oral cephalosporin, CL 284,635, in various species. Drug Metabolism and Disposition [Internet]. 1986;14(1):132–6. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0022580683&partnerID=40&md5=8d5578e15e008a5085082a0a133f84e9
244.
Bialer M, Friedman M, Dubrovsky J. Relation between absorption half‐life values of four novel sustained‐release dosage forms of valproic acid in dogs and human. Biopharmaceutics & Drug Disposition [Internet]. 1986;7(5):495–500. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0022523020&doi=10.1002%252fbdd.2510070510&partnerID=40&md5=95ebc8d63c9faf9309d9ffade6576897
245.
Yagen B, Sintov A, Bialer M. New, sensitive thin-layer chromatographic-high-performance liquid chromatographic method for detection of trichothecene mycotoxins. Journal of Chromatography A [Internet]. 1986;356(C):195–201. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0022492846&doi=10.1016%2fS0021-9673%2800%2991479-1&partnerID=40&md5=788a0ce7d3db395cfec3a448c748829e
246.
Bialer M, Salame K, Raz I. Effect of sustained-release on the pharmacokinetics of theophylline in healthy subjects. International Journal of Clinical Pharmacology Therapy and Toxicology [Internet]. 1985;23(12):662–7. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0022365251&partnerID=40&md5=21f4eafe7b8747cab6186245cf113da0
247.
Tonelli AP, Bialer M, Yacobi A. Relationship between protein binding and renal clearance of a new oral cephalosporin in the dog. Journal of Pharmaceutical Sciences [Internet]. 1985;74(11):1242–4. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0022413331&doi=10.1002%252fjps.2600741122&partnerID=40&md5=956ee2c26151c9dd659c9443f9e9fbf1
248.
Yagen B, Bialer M, Sintov A. Gas chromatographic assay with pharmacokinetic applications for monitoring T-2 and HT-2 toxins in plasma. Journal of Chromatography B: Biomedical Sciences and Applications [Internet]. 1985;343(C):67–75. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0022357864&doi=10.1016%2fS0378-4347%2800%2984569-7&partnerID=40&md5=5eea0b66f3b8f0dbafaa48d968eefada
249.
Bialer M, Friedman M, Dubrovsky J, Raz I, Abramsky O. Pharmacokinetic evaluation of novel sustained‐release dosage forms of valproic acid in humans. Biopharmaceutics & Drug Disposition [Internet]. 1985;6(4):401–11. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0022353428&doi=10.1002%252fbdd.2510060406&partnerID=40&md5=3d5427688e8284998dbe2a6ac4021652
250.
Bialer M, Hussein Z, Raz I, Abramsky O, Herishanu Y, Pachys F. Pharmacokinetics of valproic acid in volunteers after a single dose study. Biopharmaceutics & Drug Disposition [Internet]. 1985;6(1):33–42. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0021999254&doi=10.1002%252fbdd.2510060105&partnerID=40&md5=e2f94f9d513d5ef2f6c913bbb8a7607b
251.
Bialer M, Hoch B. Rapid gas chromatographic assay for monitoring valnoctamide in plasma. Journal of Chromatography B: Biomedical Sciences and Applications [Internet]. 1985;337(C):408–11. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0021957017&doi=10.1016%2f0378-4347%2885%2980055-4&partnerID=40&md5=0e661208f3605e67d67d04de2f545c14
252.
Bialer M, Rubinstein A, Dubrovsky J, Raz I, Abramsky O. A comparative pharmacokinetic study of valpromide and valproic acid after intravenous administration in humans. International Journal of Pharmaceutics [Internet]. 1985;23(1):25–33. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0021948924&doi=10.1016%2f0378-5173%2885%2990219-4&partnerID=40&md5=85a7d16acc8f3c1650bd38383d217eb4
253.
Bialer M, Hussein Z, Dubrovsky J, Raz I, Abramsky O. Pharmacokinetics of valproic acid obtained after administration of three oral formulations to humans. Israel Journal of Medical Sciences [Internet]. 1984;20(1):46–9. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0021362216&partnerID=40&md5=37e92aa79e15ecd8a6353c4b07ce8f01
254.
Bialer M, Rubinstein A, Raz I, Abramsky O. Pharmacokinetics of valpromide after oral administration of a solution and a tablet to healthy volunteers. European Journal of Clinical Pharmacology [Internet]. 1984;27(4):501–3. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0021677679&doi=10.1007%252fBF00549603&partnerID=40&md5=a19fbd0c93bbc7434738c2b07e428d2a
255.
Raz I, Bialer M, Salame K, Bar-On H. Comparative pharmacokinetic analysis of a novel sustained-release dosage form of theophylline in humans. European Journal of Clinical Pharmacology [Internet]. 1984;26(3):401–3. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0021356144&doi=10.1007%252fBF00548775&partnerID=40&md5=34851a1687f2181004ece1c70dc35890
256.
Bialer M, Friedman M, Dubrovsky J. Comparative pharmacokinetic analysis of a novel sustained release dosage form of valproic acid in dogs. Biopharmaceutics & Drug Disposition [Internet]. 1984;5(1):1–10. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0021333759&doi=10.1002%252fbdd.2510050102&partnerID=40&md5=b09cb6671b971b850b677348098e4ea2
257.
Bialer M, Friedman M, Dubrovsky J. Effect of sustained release on the pharmacokinetics of valproic acid in the dog. International Journal of Pharmaceutics [Internet]. 1984;20(1–2):53–63. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0021279919&doi=10.1016%2f0378-5173%2884%2990217-5&partnerID=40&md5=b9f0125adc42bc0f7e74b8ce4ec176a1
258.
Bialer M, Friedman M, Rubinstein A. Rapid gas chromatographic assay for monitoring valproic acid and valpromide in plasma. Journal of Pharmaceutical Sciences [Internet]. 1984;73(7):991–3. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0021270970&doi=10.1002%252fjps.2600730734&partnerID=40&md5=54b9b43e246d537b78d672e7021e5825
259.
Bialer M, Rubinstein A. Pharmacokinetics of valpromide in dogs after various modes of administration. Biopharmaceutics & Drug Disposition [Internet]. 1984;5(2):177–83. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0021260414&doi=10.1002%252fbdd.2510050211&partnerID=40&md5=1c1b7bce9aaffe67b8266621831e7add
260.
Bialer M, Sloneker SD, Kostenbauder HB. Isolation of a cigarette smoke fraction responsible for the inhibition of benzo[a]pyrene metabolism in the isolated perfused rabbit lung. Chemico-Biological Interactions [Internet]. 1984;51(3):309–20. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0021225936&doi=10.1016%2f0009-2797%2884%2990156-X&partnerID=40&md5=49d88898b6f24cd87b0093fad412f936
261.
Johno I, Bialer M, Nickelson SA, Levy RH. Disposition of Progabide and Valproic Acid Following Intraperitoneal Administration in Rhesus Monkey. Epilepsia [Internet]. 1984;25(5):578–85. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0021181232&doi=10.1111%252fj.1528-1157.1984.tb03465.x&partnerID=40&md5=feefa14a1902904ec04dbf026ae3fadd
262.
Bialer M. Estimation of pharmacokinetic parameters in extravascular multiple dose administration in the one-compartment open body model with equal absorption and elimination first-order rate constants. International Journal of Pharmaceutics [Internet]. 1983;13(3):345–8. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0020663233&doi=10.1016%2f0378-5173%2883%2990083-2&partnerID=40&md5=4c421e8276e815eb45cbdd9e6f6f7efc
263.
Bialer M, Hussein Z, Herishanu Y, Melnik Y. An alternative method for calculating absorption and elimination rate constants in first-order processes: application to valproic acid. International Journal of Pharmaceutics [Internet]. 1983;16(3):285–94. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0020610244&doi=10.1016%2f0378-5173%2883%2990147-3&partnerID=40&md5=a37fca699436dee5d64871b6eb207c6a
264.
Bialer M, Rubinstein A. A comparative study on the pharmacokinetics of valpramide after intravenous administration in dogs. Journal of Pharmacy and Pharmacology [Internet]. 1983;35(9):607–9. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0020604494&doi=10.1111%252fj.2042-7158.1983.tb04347.x&partnerID=40&md5=a126f23712d1178a13763d08f3fd22b7
265.
Garrett ER, Green Jr JR, Bialer M. Bretylium pharmacokinetics and bioavailabilities in man with various doses and modes of administration. Biopharmaceutics & Drug Disposition [Internet]. 1982;3(2):129–64. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0020327294&doi=10.1002%252fbdd.2510030206&partnerID=40&md5=e8f059664863ce9252d6aa26b7365058
266.
Bialer M. An unusual cleavage of ring D in Δ14-17-keto steroid after a reaction with alkaline hydrogen peroxide. Tetrahedron Letters [Internet]. 1981;22(28):2683–4. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-49149136087&doi=10.1016%2fS0040-4039%2801%2992969-7&partnerID=40&md5=b220e402ac37f6f58a955a75020bf659
267.
Bialer M, El‐On J, Yagen B, Mechoulam R. Antiparasitic structure‐activity relationships of congocidine derivatives. Journal of Pharmaceutical Sciences [Internet]. 1981;70(7):822–4. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0019870538&doi=10.1002%252fjps.2600700735&partnerID=40&md5=6fdcd884181863044c8e4f021fffa51e
268.
Bourne DWA, Bialer M, Dittert LW, Hayashi M, Rudawsky G, Koritz GD, et al. Disposition of sulfadimethoxine in cattle: Inclusion of protein binding factors in a pharmacokinetic model. Journal of Pharmaceutical Sciences [Internet]. 1981;70(9):1068–72. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0019828004&doi=10.1002%252fjps.2600700926&partnerID=40&md5=8766edabed1547a91ae7b6794f94ed9f
269.
Bialer M. An alternative method for calculating simple pharmacokinetic parameters for zero‐order absorption and first‐order elimination processes. Biopharmaceutics & Drug Disposition [Internet]. 1981;2(4):323–7. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0019824339&doi=10.1002%252fbdd.2510020404&partnerID=40&md5=3e4a7f6b00e42c8830e4f01e26ea0321
270.
Bialer M, Yagen B, Mechoulam R, Becker Y. Structure-Activity Relationships of Pyrrole Amidine Antiviral Antibiotics. 2. Preparation of Mono-and Tripyrrole Derivatives of Congocidine. Journal of Medicinal Chemistry [Internet]. 1980;23(10):1144–8. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0019186958&doi=10.1021%252fjm00184a018&partnerID=40&md5=50a6baf231926438d179e64dafb0da9f
271.
Bialer M. A simple method for determining whether absorption and elimination rate constants are equal in the one-compartment open model with first-order processes. Journal of Pharmacokinetics and Biopharmaceutics [Internet]. 1980;8(1):111–3. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0018906187&doi=10.1007%252fBF01059453&partnerID=40&md5=5b144fc9a9d0dbf1cc20d6027f1d453b
272.
Bialer M, Yagen B, Mechoulam R, Becker Y. Structure–activity relationships of pyrrole amidine antiviral antibiotics III: Preparation of distamycin and congocidine derivatives based on 2,5‐disubstituted pyrroles. Journal of Pharmaceutical Sciences [Internet]. 1980;69(11):1334–8. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0019257423&doi=10.1002%252fjps.2600691125&partnerID=40&md5=757afa306a2e971df0a91b6d3dc386ad
273.
Bialer M, Yagen B, Mechoulam R. Structure elucidation of a condensation product of 4‐aminopyrrole derivatives and dicyclohexylcarbodiimide. Journal of Heterocyclic Chemistry [Internet]. 1980;17(8):1797–8. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0019176806&doi=10.1002%252fjhet.5570170834&partnerID=40&md5=0515ac0a128d1b1638a44a381e2fcb5a
274.
Bialer M, Yagen B, Mechoulam R, Becker Y. Structure-Activity Relationships of Pyrrole Amidine Antiviral Antibiotics. 1. Modifications of the Alkylamidine Side Chain. Journal of Medicinal Chemistry [Internet]. 1979;22(11):1296–301. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0018639797&doi=10.1021%252fjm00197a004&partnerID=40&md5=f7fe40581342d6f580c49705d1bc1d4a
275.
Bialer M, Yagen B, Mechoulam R. A total synthesis of distamycin a, an antiviral antibiotic. Tetrahedron [Internet]. 1978;34(15):2389–91. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0000515208&doi=10.1016%2f0040-4020%2878%2989056-5&partnerID=40&md5=8e0235715d559845cae2fb5e241204e2